

Psilocybin produces substantial and sustained decrease
patients with life-threatening cancer: A randomized do

Journal of Psychopharmacology

30, 1181-1197

DOI: [10.1177/0269881116675513](https://doi.org/10.1177/0269881116675513)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Back to the future: Research renewed on the clinical utility of psychedelic drugs. Journal of Psychopharmacology, 2016, 30, 1198-1200.	2.0	7
2	Psilocybin: Psychotherapy or drug?. Journal of Psychopharmacology, 2016, 30, 1201-1202.	2.0	5
3	Psilocybin in end of life care: Implications for further research. Journal of Psychopharmacology, 2016, 30, 1203-1204.	2.0	4
4	Psycho-existential distress in cancer patients: A return to "entheogens". Journal of Psychopharmacology, 2016, 30, 1205-1206.	2.0	11
5	Psilocybin and palliative end-of-life care. Journal of Psychopharmacology, 2016, 30, 1207-1208.	2.0	10
6	Psilocybin for depression and anxiety associated with life-threatening illnesses. Journal of Psychopharmacology, 2016, 30, 1209-1210.	2.0	14
7	The successful return of psychedelics to psychiatry. Journal of Psychopharmacology, 2016, 30, 1211-1211.	2.0	5
8	The role of psychedelics in palliative care reconsidered: A case for psilocybin. Journal of Psychopharmacology, 2016, 30, 1212-1214.	2.0	6
9	Psilocybin-assisted psychotherapy for dying cancer patients "aiding the final trip. Journal of Psychopharmacology, 2016, 30, 1215-1217.	2.0	8
10	Psilocybin: promising results in double-blind trials require confirmation by real-world evidence. Journal of Psychopharmacology, 2016, 30, 1218-1219.	2.0	3
11	Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future. Journal of Psychopharmacology, 2016, 30, 1163-1164.	2.0	14
12	Therapeutic Applications of Classic Hallucinogens. Current Topics in Behavioral Neurosciences, 2016, 36, 361-391.	0.8	60
13	The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology, 2016, 30, 1279-1295.	2.0	175
14	Hallucinogenic Drugs: A New Study Answers Old Questions about LSD. Current Biology, 2017, 27, R156-R158.	1.8	7
15	Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. Current Topics in Behavioral Neurosciences, 2017, 36, 393-430.	0.8	152
16	Should addiction researchers be interested in psychedelic science?. Drug and Alcohol Review, 2017, 36, 285-287.	1.1	4
17	Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders. Journal of Psychoactive Drugs, 2017, 49, 446-455.	1.0	49
18	Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis. Journal of Humanistic Psychology, 2017, 57, 354-388.	1.4	173

#	ARTICLE	IF	CITATIONS
19	The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. <i>Neuropsychopharmacology</i> , 2017, 42, 2105-2113.	2.8	364
20	Modern Clinical Research on LSD. <i>Neuropsychopharmacology</i> , 2017, 42, 2114-2127.	2.8	146
21	Psychedelics, Personality and Political Perspectives. <i>Journal of Psychoactive Drugs</i> , 2017, 49, 182-191.	1.0	155
22	Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress. <i>Journal of Humanistic Psychology</i> , 2017, 57, 488-519.	1.4	94
23	Patients' Accounts of Increased "Connectedness" and "Acceptance" After Psilocybin for Treatment-Resistant Depression. <i>Journal of Humanistic Psychology</i> , 2017, 57, 520-564.	1.4	309
24	Comparison of the Psychopharmacological Effects of Tiletamine and Ketamine in Rodents. <i>Neurotoxicity Research</i> , 2017, 32, 544-554.	1.3	22
25	Potential Therapeutic Effects of Psilocybin. <i>Neurotherapeutics</i> , 2017, 14, 734-740.	2.1	180
26	Psilocybin: Good Trip or Bad Trip. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 580-584.	2.3	15
27	Beyond serotonin: newer antidepressants in the future. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 777-790.	1.4	20
28	Neuroticism is associated with challenging experiences with psilocybin mushrooms. <i>Personality and Individual Differences</i> , 2017, 117, 155-160.	1.6	54
29	Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1543-1554.	1.6	107
30	Psychedelic Drugs in Biomedicine. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 992-1005.	4.0	113
32	Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. <i>Scientific Reports</i> , 2017, 7, 13187.	1.6	346
34	NATURALIZING PSYCHEDELIC SPIRITUALITY. <i>Zygon</i> , 2017, 52, 623-642.	0.2	10
35	Psychedelic pleasures: An affective understanding of the joys of tripping. <i>International Journal of Drug Policy</i> , 2017, 49, 133-143.	1.6	32
36	Serotonin and brain function: a tale of two receptors. <i>Journal of Psychopharmacology</i> , 2017, 31, 1091-1120.	2.0	440
37	Lessons to be learned from early psychedelic therapy in Denmark. <i>Nordic Journal of Psychiatry</i> , 2017, 71, 487-488.	0.7	10
39	LSD treatment in Scandinavia: emphasizing indications and short-term treatment outcomes of 151 patients in Denmark. <i>Nordic Journal of Psychiatry</i> , 2017, 71, 489-495.	0.7	9

#	ARTICLE	IF	CITATIONS
40	The alkaloids of <i>Banisteriopsis caapi</i> , the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro. <i>Scientific Reports</i> , 2017, 7, 5309.	1.6	112
41	Developing Guidelines and Competencies for the Training of Psychedelic Therapists. <i>Journal of Humanistic Psychology</i> , 2017, 57, 450-487.	1.4	103
42	The Effects of Hallucinogens on Gene Expression. <i>Current Topics in Behavioral Neurosciences</i> , 2017, 36, 137-158.	0.8	33
43	Self unbound: ego dissolution in psychedelic experience. <i>Neuroscience of Consciousness</i> , 2017, 2017, nix016.	1.4	87
44	New medications for treatment-resistant depression: a brief review of recent developments. <i>CNS Spectrums</i> , 2017, 22, 39-48.	0.7	11
45	Jeremy Shaw's DMT. <i>Performance Research</i> , 2017, 22, 43-53.	0.2	0
46	Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions. <i>Frontiers in Psychology</i> , 2017, 8, 1238.	1.1	28
47	Psilocybin-assisted therapy for anxiety and depression: implications for euthanasia. <i>Medical Journal of Australia</i> , 2017, 206, 468-469.	0.8	1
48	Ayahuasca: what mental health professionals need to know. <i>Revista De Psiquiatria Clinica</i> , 2017, 44, 103-109.	0.6	8
50	Psychedelics: Where we are now, why we got here, what we must do. <i>Neuropharmacology</i> , 2018, 142, 7-19.	2.0	96
51	Powerful substances in tiny amounts. <i>NAD Nordic Studies on Alcohol and Drugs</i> , 2018, 35, 39-51.	0.7	114
52	Should Australian Psychology Consider Enhancing Psychotherapeutic Interventions with Psychedelic Drugs? A Call for Research. <i>Australian Psychologist</i> , 2018, 53, 467-476.	0.9	7
53	Psychedelics and the essential importance of context. <i>Journal of Psychopharmacology</i> , 2018, 32, 725-731.	2.0	357
54	The hidden therapist: evidence for a central role of music in psychedelic therapy. <i>Psychopharmacology</i> , 2018, 235, 505-519.	1.5	131
55	Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. <i>Journal of Psychopharmacology</i> , 2018, 32, 811-819.	2.0	97
56	Taking Psychedelics Seriously. <i>Journal of Palliative Medicine</i> , 2018, 21, 417-421.	0.6	91
57	Psychiatry & the psychedelic drugs. Past, present & future. <i>Neuropharmacology</i> , 2018, 142, 200-218.	2.0	222
58	Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. <i>Neuropharmacology</i> , 2018, 142, 263-269.	2.0	126

#	ARTICLE	IF	CITATIONS
59	Ketamine: A Promising Rapid-Acting Antidepressant. , 2018, , 223-239.		3
60	A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. <i>Neuropharmacology</i> , 2018, 142, 270-276.	2.0	44
61	Integrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model Clinic. , 2018, , 113-132.		10
62	Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role?. <i>Pain Management</i> , 2018, 8, 217-229.	0.7	31
63	Plant Medicines, Healing and Psychedelic Science. , 2018, , .		7
64	Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action. <i>Handbook of Experimental Pharmacology</i> , 2018, 252, 227-260.	0.9	23
65	The use of antidepressants in oncology: a review and practical tips for oncologists. <i>Annals of Oncology</i> , 2018, 29, 101-111.	0.6	48
66	Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. <i>Psychopharmacology</i> , 2018, 235, 459-466.	1.5	62
67	Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 1-10.	2.5	79
68	Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. <i>Journal of Psychopharmacology</i> , 2018, 32, 49-69.	2.0	285
69	The relationships of classic psychedelic use with criminal behavior in the United States adult population. <i>Journal of Psychopharmacology</i> , 2018, 32, 37-48.	2.0	61
70	Psychedelic Drugs as Therapeutics: No Illusions About the Challenges. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 561-564.	2.3	21
71	The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant. <i>Psychopharmacology</i> , 2018, 235, 551-560.	1.5	49
72	Long-lasting subjective effects of LSD in normal subjects. <i>Psychopharmacology</i> , 2018, 235, 535-545.	1.5	137
73	Studies with psychedelic drugs in human volunteers. <i>Neuropharmacology</i> , 2018, 142, 116-134.	2.0	23
74	Novel psychotherapeutics â€“ a cautiously optimistic focus on Hallucinogens. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1-3.	1.3	26
75	Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. <i>Psychopharmacology</i> , 2018, 235, 399-408.	1.5	537
76	Pharmacies as potential providers of harm reduction services: A preliminary online survey. <i>Drug Science, Policy and Law</i> , 2018, 4, 205032451876744.	0.6	4

#	ARTICLE	IF	CITATIONS
77	Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. <i>ELife</i> , 2018, 7, .	2.8	244
79	Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study. <i>Frontiers in Psychology</i> , 2018, 9, 2459.	1.1	54
80	Implications of Behavioral Narratology for Psychotherapy, Help-Seeking Behavior, and Substance Use. <i>Perspectives on Behavior Science</i> , 2018, 41, 517-540.	1.1	6
81	Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. <i>International Review of Psychiatry</i> , 2018, 30, 291-316.	1.4	115
82	“To learn healing knowledge”: Philosophy, psychedelic studies and transformation. <i>South African Journal of Philosophy</i> , 2018, 37, 438-451.	0.3	2
83	Psychiatry might need some psychedelic therapy. <i>International Review of Psychiatry</i> , 2018, 30, 285-290.	1.4	8
84	The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training. <i>Journal of Psychedelic Studies</i> , 2018, 2, 64-73.	0.5	64
85	The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women. <i>Journal of Psychopharmacology</i> , 2018, 32, 1385-1391.	2.0	22
86	Psychedelics and music: neuroscience and therapeutic implications. <i>International Review of Psychiatry</i> , 2018, 30, 350-362.	1.4	41
87	Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. <i>International Review of Psychiatry</i> , 2018, 30, 331-342.	1.4	98
88	The renaissance in psychedelic research: What do preclinical models have to offer. <i>Progress in Brain Research</i> , 2018, 242, 25-67.	0.9	20
89	More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression. <i>Frontiers in Psychology</i> , 2018, 9, 1721.	1.1	26
90	Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting. <i>Psychopharmacology</i> , 2018, 235, 3401-3413.	1.5	102
91	Everything old is new again: are psychedelic medicines poised to take mental health by storm?. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 365-367.	2.2	0
92	Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. <i>Journal of Psychopharmacology</i> , 2018, 32, 1286-1294.	2.0	61
93	d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders. <i>Progress in Brain Research</i> , 2018, 242, 69-96.	0.9	61
95	Facile assembly and fluorescence-based screening method for heterologous expression of biosynthetic pathways in fungi. <i>Metabolic Engineering</i> , 2018, 48, 44-51.	3.6	57
96	Dark Classics in Chemical Neuroscience: Mescaline. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2448-2458.	1.7	47

#	ARTICLE	IF	CITATIONS
97	Psychedelic use and intimate partner violence: The role of emotion regulation. <i>Journal of Psychopharmacology</i> , 2018, 32, 749-755.	2.0	35
98	A Survey of American Psychiatrists' Attitudes Toward Classic Hallucinogens. <i>Journal of Nervous and Mental Disease</i> , 2018, 206, 476-480.	0.5	47
99	Psychedelics and hypnosis: Commonalities and therapeutic implications. <i>Journal of Psychopharmacology</i> , 2018, 32, 732-740.	2.0	17
100	Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. <i>Journal of Psychopharmacology</i> , 2018, 32, 756-769.	2.0	152
101	High dose psilocybin is associated with positive subjective effects in healthy volunteers. <i>Journal of Psychopharmacology</i> , 2018, 32, 770-778.	2.0	46
102	DARK Classics in Chemical Neuroscience: Psilocybin. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2438-2447.	1.7	68
103	Mental health in patients with advanced cancer at the end of life: evaluation of evidence and future directions. <i>Expert Review of Quality of Life in Cancer Care</i> , 2018, 3, 73-94.	0.6	7
104	Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. <i>Psychopharmacology</i> , 2018, 235, 2915-2927.	1.5	58
105	Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. <i>Frontiers in Pharmacology</i> , 2017, 8, 974.	1.6	454
106	Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder. <i>Frontiers in Pharmacology</i> , 2018, 9, 100.	1.6	76
107	The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions. <i>Frontiers in Pharmacology</i> , 2018, 9, 132.	1.6	70
108	Unifying Theories of Psychedelic Drug Effects. <i>Frontiers in Pharmacology</i> , 2018, 9, 172.	1.6	107
109	Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics. <i>Frontiers in Pharmacology</i> , 2018, 9, 177.	1.6	29
110	Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. <i>Frontiers in Pharmacology</i> , 2018, 9, 256.	1.6	62
111	Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. <i>Frontiers in Pharmacology</i> , 2018, 9, 733.	1.6	115
112	Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls. <i>Frontiers in Psychiatry</i> , 2018, 9, 185.	1.3	83
113	Psilocybin and Mental Health—“Don't Lose Control. <i>Frontiers in Psychiatry</i> , 2018, 9, 293.	1.3	13
114	Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 889-902.	1.3	134

#	ARTICLE	IF	CITATIONS
115	Predicting Responses to Psychedelics: A Prospective Study. <i>Frontiers in Pharmacology</i> , 2018, 9, 897.	1.6	226
116	Psychedelics, Meditation, and Self-Consciousness. <i>Frontiers in Psychology</i> , 2018, 9, 1475.	1.1	179
117	Psychedelics â€œ Re-opening the doors of perception. <i>Neuropharmacology</i> , 2018, 142, 1-6.	2.0	5
118	Psychedelics as anti-inflammatory agents. <i>International Review of Psychiatry</i> , 2018, 30, 363-375.	1.4	122
119	Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. <i>International Review of Psychiatry</i> , 2018, 30, 317-330.	1.4	47
120	DMT Models the Near-Death Experience. <i>Frontiers in Psychology</i> , 2018, 9, 1424.	1.1	122
121	The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. <i>Neuropharmacology</i> , 2018, 142, 143-166.	2.0	184
122	Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. <i>Psychological Medicine</i> , 2019, 49, 655-663.	2.7	479
123	5-Methoxy-N,N-dimethyltryptamine: An Ego-Dissolving Endogenous Neurochemical Catalyst of Creativity. <i>Activitas Nervosa Superior</i> , 2019, 61, 170-216.	0.4	5
124	The influence of ketamine on drug discovery in depression. <i>Drug Discovery Today</i> , 2019, 24, 2033-2043.	3.2	57
125	Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. <i>Journal of Psychopharmacology</i> , 2019, 33, 1076-1087.	2.0	180
126	Psychedelic microdosing benefits and challenges: an empirical codebook. <i>Harm Reduction Journal</i> , 2019, 16, 43.	1.3	59
127	Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. <i>Journal of Psychopharmacology</i> , 2019, 33, 1039-1057.	2.0	121
128	Classical psychedelics for the treatment of depression and anxiety: A systematic review. <i>Journal of Affective Disorders</i> , 2019, 258, 11-24.	2.0	124
129	2018: A watershed year for psychedelic science. <i>Drug Science, Policy and Law</i> , 2019, 5, 205032451987228.	0.6	18
130	Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer. <i>BMC Psychiatry</i> , 2019, 19, 321.	1.1	11
131	Toward a contextual psychedelic-assisted therapy: Perspectives from Acceptance and Commitment Therapy and contextual behavioral science. <i>Journal of Contextual Behavioral Science</i> , 2019, 14, 136-145.	1.3	25
132	The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial. <i>Frontiers in Pharmacology</i> , 2019, 10, 1325.	1.6	44

#	ARTICLE	IF	CITATIONS
133	Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada. <i>Drug and Alcohol Review</i> , 2019, 38, 781-789.	1.1	60
134	BOVINE WELFARE HANDLED IN ADAPTED CORRAL WITH UNCONVENTIONAL MATERIALS. <i>Engenharia Agricola</i> , 2019, 39, 272-279.	0.2	0
135	Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers. <i>Frontiers in Psychiatry</i> , 2019, 10, 672.	1.3	36
136	Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. , 2019, 204, 107402.		132
137	Using the pharmacy retail model to examine perceptions and biases of a UK population sample towards regulation of specific psychoactive drugs. <i>Drug Science, Policy and Law</i> , 2019, 5, 205032451987612.	0.6	3
138	Psilocybin for depression: Considerations for clinical trial design. <i>Journal of Psychedelic Studies</i> , 2019, 3, 269-279.	0.5	6
139	The psychedelic renaissance: the next trip for psychiatry?. <i>Irish Journal of Psychological Medicine</i> , 2022, 39, 335-339.	0.7	11
140	Current status of psychedelic therapy in Australia and New Zealand: Are we falling behind?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 190-192.	1.3	15
141	Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports. <i>Consciousness and Cognition</i> , 2019, 69, 52-69.	0.8	48
142	Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. <i>Neuropsychopharmacology</i> , 2019, 44, 1328-1334.	2.8	259
143	REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. <i>Pharmacological Reviews</i> , 2019, 71, 316-344.	7.1	467
144	Ayahuasca, an ancient substance with traditional and contemporary use in neuropsychiatry and neuroscience. <i>Epilepsy and Behavior</i> , 2019, 121, 106300.	0.9	22
145	Validation of an analytical method for the determination of the main ayahuasca active compounds and application to real ayahuasca samples from Brazil. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1124, 197-203.	1.2	24
146	The Past and Future of Psychedelic Science: An Introduction to This Issue. <i>Journal of Psychoactive Drugs</i> , 2019, 51, 93-97.	1.0	43
147	Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial. <i>Frontiers in Psychology</i> , 2019, 10, 1234.	1.1	114
148	Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat. <i>Acta Neuropsychiatrica</i> , 2019, 31, 213-219.	1.0	37
149	Cessation and reduction in alcohol consumption and misuse after psychedelic use. <i>Journal of Psychopharmacology</i> , 2019, 33, 1088-1101.	2.0	145
150	Rapid-acting antidepressants. <i>Advances in Pharmacology</i> , 2019, 86, 47-96.	1.2	49

#	ARTICLE	IF	CITATIONS
151	The adrenergic receptor antagonist carvedilol interacts with serotonin 2A receptors both in vitro and in vivo. <i>Pharmacology Biochemistry and Behavior</i> , 2019, 181, 37-45.	1.3	9
153	Scientific Issues Relevant to Improving the Diagnosis, Risk Assessment, and Treatment of Major Depression. <i>American Journal of Psychiatry</i> , 2019, 176, 342-347.	4.0	15
154	Emerging from the dark side: new therapeutic applications of scheduled psychoactive substances. <i>Future Medicinal Chemistry</i> , 2019, 11, 161-164.	1.1	2
155	Psychedelic-assisted therapy for anxiety and depression in the face of death: A critical review with an anthropological lens. <i>Journal of Psychedelic Studies</i> , 2019, 3, 14-18.	0.5	1
156	5-methoxy- <i>N,N</i> -dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 161-169.	1.1	91
157	Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20 th Century. <i>Journal of Psychoactive Drugs</i> , 2019, 51, 210-217.	1.0	9
158	A single inhalation of vapor from dried toad secretion containing 5-methoxy- <i>N,N</i> -dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. <i>Psychopharmacology</i> , 2019, 236, 2653-2666.	1.5	99
159	Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice. <i>Journal of Psychopharmacology</i> , 2019, 33, 406-414.	2.0	18
160	Psychedelic therapy in the Czech Republic: A theoretical concept or a realistic goal?. <i>Journal of Psychedelic Studies</i> , 2019, 3, 19-31.	0.5	5
161	A systematic study of microdosing psychedelics. <i>PLoS ONE</i> , 2019, 14, e0211023.	1.1	143
162	Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being. <i>Journal of Psychoactive Drugs</i> , 2019, 51, 123-134.	1.0	91
163	Have no fear. <i>EMBO Reports</i> , 2019, 20, .	2.0	0
164	The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives. , 2019, , 401-413.		0
166	Pharmacotherapy of anxiety disorders in the 21st century: A call for novel approaches. <i>Annals of General Psychiatry</i> , 2019, 32, e100136.	1.1	7
167	Psychedelics for Psychological and Existential Distress in Palliative and Cancer Care. <i>Current Oncology</i> , 2019, 26, 225-226.	0.9	10
168	Seeing without self: Discovering new meaning with psychedelic-assisted psychotherapy. <i>Neuropsychoanalysis</i> , 2019, 21, 53-78.	0.1	18
169	Modulation of Social Cognition via Hallucinogens and "Entactogens". <i>Frontiers in Psychiatry</i> , 2019, 10, 881.	1.3	29
170	Depressive Disorders: Mechanisms, Measurement and Management. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	6

#	ARTICLE	IF	CITATIONS
171	Psychedelics and potential benefits in "healthy normals": A review of the literature. <i>Journal of Psychedelic Studies</i> , 2019, 3, 280-287.	0.5	15
172	The role of Indigenous knowledges in psychedelic science. <i>Journal of Psychedelic Studies</i> , 2019, 4, 16-23.	0.5	33
173	Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. <i>Scientific Reports</i> , 2019, 9, 14914.	1.6	79
174	Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. <i>Psychopharmacology</i> , 2019, 236, 731-740.	1.5	104
175	"Go Ask Alice": The Case for Researching Schedule I Drugs. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2019, 28, 168-177.	0.5	2
176	Trait Openness and serotonin 2A receptors in healthy volunteers: A positron emission tomography study. <i>Human Brain Mapping</i> , 2019, 40, 2117-2124.	1.9	8
177	How do psychedelics work?. <i>Current Opinion in Psychiatry</i> , 2019, 32, 16-21.	3.1	73
178	Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. , 2019, 197, 83-102.		296
179	Attending to the Quality of Life at the End of Life. Palliative Rehabilitation Is Person-Centered Care for Patients With Advanced Cancer. , 2019, , 161-175.		0
180	Palliative Nursing and Sacred Medicine: A Holistic Stance on Entheogens, Healing, and Spiritual Care. <i>Journal of Holistic Nursing</i> , 2019, 37, 100-106.	0.6	15
181	Can Psychedelic Drugs Attenuate Age-Related Changes in Cognition and Affect?. <i>Journal of Cognitive Enhancement: Towards the Integration of Theory and Practice</i> , 2020, 4, 219-227.	0.8	12
182	Exploring the case for research on incorporating psychedelics within interventions for borderline personality disorder. <i>Journal of Contextual Behavioral Science</i> , 2020, 15, 1-11.	1.3	47
183	DARK Classics in Chemical Neuroscience: NBOMes. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3860-3869.	1.7	39
184	Ayahuasca's "afterglow": improved mindfulness and cognitive flexibility in ayahuasca drinkers. <i>Psychopharmacology</i> , 2020, 237, 1161-1169.	1.5	72
185	Social Work and Psychedelic-Assisted Therapies: Practice Considerations for Breakthrough Treatments. <i>Clinical Social Work Journal</i> , 2021, 49, 356-367.	1.3	6
186	The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. <i>Psychiatry Research</i> , 2020, 284, 112749.	1.7	104
187	An Improved, Practical, and Scalable Five-Step Synthesis of Psilocybin. <i>Synthesis</i> , 2020, 52, 688-694.	1.2	12
188	Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. <i>Neuropharmacology</i> , 2020, 167, 107933.	2.0	132

#	ARTICLE	IF	CITATIONS
189	Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. <i>Journal of Psychopharmacology</i> , 2020, 34, 155-166.	2.0	171
190	Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. <i>Psychopharmacology</i> , 2020, 237, 841-853.	1.5	83
191	Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. <i>Journal of Contextual Behavioral Science</i> , 2020, 15, 39-45.	1.3	172
192	Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. <i>Neuropsychopharmacology</i> , 2020, 45, 462-471.	2.8	141
193	Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials. <i>Frontiers in Psychiatry</i> , 2019, 10, 943.	1.3	80
194	Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. <i>Psychopharmacology</i> , 2020, 237, 773-785.	1.5	61
195	Psilocybin-assisted therapy for depression: How do we advance the field?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 225-231.	1.3	9
196	Therapeutic use of serotonergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 108, 423-434.	2.9	82
197	Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics. <i>Psychopharmacology</i> , 2020, 237, 21-32.	1.5	27
198	Microdosing psychedelics: Motivations, subjective effects and harm reduction. <i>International Journal of Drug Policy</i> , 2020, 75, 102600.	1.6	50
199	Treatment of a Complex Personality Disorder Using Repeated Doses of LSD—A Case Report on Significant Improvements in the Absence of Acute Drug Effects. <i>Frontiers in Psychiatry</i> , 2020, 11, 573953.	1.3	22
200	Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. <i>EClinicalMedicine</i> , 2020, 27, 100538.	3.2	138
201	Commercialization and Conservation. , 2020, , 97-106.		0
203	Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 119, 194-203.	2.9	33
204	The Effectiveness of Dignity Therapy as Applied to End-of-Life Patients with Cancer in Taiwan: A Quasi-Experimental Study. <i>Asian Nursing Research</i> , 2020, 14, 189-195.	0.7	11
205	Perceived harm, motivations for use and subjective experiences of recreational psychedelic "magic" mushroom use. <i>Journal of Psychopharmacology</i> , 2020, 34, 999-1007.	2.0	9
206	Nonlinear Dynamics and Navigating the End of Life. <i>Annals of Family Medicine</i> , 2020, 18, 484-485.	0.9	0
207	Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review. <i>Molecular Biology Reports</i> , 2020, 47, 9791-9799.	1.0	33

#	ARTICLE	IF	CITATIONS
208	MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. <i>Scientific Reports</i> , 2020, 10, 20442.	1.6	70
209	Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use. <i>ACS Omega</i> , 2020, 5, 32067-32075.	1.6	15
210	Advancing elite athlete mental health treatment with psychedelic-assisted psychotherapy. <i>Journal of Applied Sport Psychology</i> , 2020, , 1-19.	1.4	1
211	Propri�t�s �golytiques des psych�d�liques et int�r�ts dans le traitement de la d�pression. <i>Psychologie Francaise</i> , 2020, 66, 303-303.	0.2	0
212	Mercurius Ubiquitous. <i>International Journal of Jungian Studies</i> , 2020, 13, 13-40.	0.2	1
213	At the Intersection of Palliative Care, Psychedelic Medicine, and Healthcare Reform: A Call for a New Hospice and Palliative Care Movement. <i>Journal of Palliative Care</i> , 2020, , 082585972094689.	0.4	1
214	Ketamine beyond anesthesia: Antidepressant effects and abuse potential. <i>Behavioural Brain Research</i> , 2020, 394, 112841.	1.2	9
215	Psychedelics and virtual reality: parallels and applications. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532094835.	1.2	15
216	Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation. <i>Frontiers in Psychiatry</i> , 2020, 11, 782.	1.3	54
217	Addressing fear of death and dying: traditional and innovative interventions. <i>Mortality</i> , 2022, 27, 18-37.	0.3	6
218	What Are Club Drugs and NPS and Why Are They Important?. , 2020, , 3-4.		0
219	A Brief History of NPS Production and Distribution. , 2020, , 5-10.		0
220	Classification Framework for Club Drugs and NPS. , 2020, , 11-12.		0
221	The Clinical Challenge of Club Drugs and NPS. , 2020, , 13-22.		0
222	Stimulant Drugs: Introduction. , 2020, , 23-30.		0
223	Stimulant Drugs: Cocaine. , 2020, , 31-36.		0
224	Stimulant Drugs: Amphetamine-Type Stimulants. , 2020, , 37-37.		0
225	Stimulant Drugs: Synthetic Cathinones. , 2020, , 54-60.		0

#	ARTICLE	IF	CITATIONS
226	Depressant Drugs: Introduction. , 2020, , 61-61.		0
227	Depressant Drugs: Gamma-Hydroxybutyrate (GHB) and Gamma-Butyrolactone (GBL). , 2020, , 62-70.		0
228	Depressant Drugs: Fentanyl, Fentanyl Analogues and Other Opioid NPS. , 2020, , 71-77.		0
229	Depressant Drugs: Benzodiazepine NPS. , 2020, , 78-80.		0
230	Depressant Drugs: Ketamine and Its Analogues. , 2020, , 81-88.		0
231	Synthetic Cannabinoid Receptor Agonists (SCRAs). , 2020, , 89-98.		0
232	Hallucinogens. , 2020, , 99-106.		0
233	The emerging role of psilocybin and MDMA in the treatment of mental illness. Expert Review of Neurotherapeutics, 2020, 20, 1263-1273.	1.4	29
234	Stimulant Drugs: Methamphetamine. , 2020, , 38-45.		0
235	Stimulant Drugs: MDMA and Drugs with Similar Effects. , 2020, , 46-53.		0
238	Psychedelics as a Treatment for Alzheimerâ€™s Disease Dementia. Frontiers in Synaptic Neuroscience, 2020, 12, 34.	1.3	28
241	Are Psychedelics Something New in Teaching Psychopharmacology?. Academic Psychiatry, 2020, 44, 511-514.	0.4	0
242	Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor. Cell, 2020, 182, 1574-1588.e19.	13.5	270
243	Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nature Reviews Neuroscience, 2020, 21, 611-624.	4.9	244
244	Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseasesâ€”A Systematic Review and Meta-Analysis of Clinical Trials. Biomedicines, 2020, 8, 331.	1.4	51
245	Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies. CNS Drugs, 2020, 34, 925-946.	2.7	87
246	The History of Psychedelics in Psychiatry. Pharmacopsychiatry, 2021, 54, 151-166.	1.7	55
247	The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health. Health Psychology Open, 2020, 7, 205510292097812.	0.7	32

#	ARTICLE	IF	CITATIONS
248	Acute Lysergic Acid Diethylamide Does Not Influence Reward-Driven Decision Making of C57BL/6 Mice in the Iowa Gambling Task. <i>Frontiers in Pharmacology</i> , 2020, 11, 602770.	1.6	7
250	Psychedelic-assisted therapy for functional neurological disorders: A theoretical framework and review of prior reports. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00688.	1.1	8
251	The ritual use of ayahuasca during treatment of severe physical illnesses: a qualitative study. <i>Journal of Psychoactive Drugs</i> , 2021, 53, 272-282.	1.0	13
252	Living with Metastatic Cancer: A Roadmap for Future Research. <i>Cancers</i> , 2020, 12, 3684.	1.7	26
253	Toxicology and Analysis of Psychoactive Tryptamines. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9279.	1.8	29
254	Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2020, 50, 2655-2666.	2.7	33
255	Psychedelic treatment of functional neurological disorder: a systematic review. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532091212.	1.2	21
256	Chronic pain and psychedelics: a review and proposed mechanism of action. <i>Regional Anesthesia and Pain Medicine</i> , 2020, 45, 486-494.	1.1	62
257	Psilocybin: from ancient magic to modern medicine. <i>Journal of Antibiotics</i> , 2020, 73, 679-686.	1.0	72
258	Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 655-670.	1.3	41
259	Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review. <i>Behavioural Brain Research</i> , 2020, 392, 112629.	1.2	21
260	Broadening Your Mind to Include Others: The relationship between serotonergic psychedelic experiences and maladaptive narcissism. <i>Psychopharmacology</i> , 2020, 237, 2725-2737.	1.5	32
261	Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. <i>Neuropsychopharmacology</i> , 2020, 45, 2003-2011.	2.8	127
262	Compassionate use of psychedelics. <i>Medicine, Health Care and Philosophy</i> , 2020, 23, 485-496.	0.9	10
263	Automated detection of the head-twitch response using wavelet scalograms and a deep convolutional neural network. <i>Scientific Reports</i> , 2020, 10, 8344.	1.6	27
264	Ethics and ego dissolution: the case of psilocybin. <i>Journal of Medical Ethics</i> , 2021, 47, 807-814.	1.0	59
265	A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy. <i>Journal of Psychoactive Drugs</i> , 2020, 52, 289-299.	1.0	89
266	Psilocybin occasioned mystical-type experiences. <i>Human Psychopharmacology</i> , 2020, 35, e2742.	0.7	16

#	ARTICLE	IF	CITATIONS
267	Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. <i>Psychopharmacology</i> , 2020, 237, 2485-2497.	1.5	103
268	Central 5-HT receptors and their function; present and future. <i>Neuropharmacology</i> , 2020, 177, 108155.	2.0	104
269	An affective neuroscience model of boosting resilience in adults. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 115, 321-350.	2.9	53
270	Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland. <i>Journal of Psychoactive Drugs</i> , 2020, 52, 309-318.	1.0	18
271	Long-term effects of psychedelic drugs: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 113, 179-189.	2.9	96
272	Natural Psychoplastogens As Antidepressant Agents. <i>Molecules</i> , 2020, 25, 1172.	1.7	10
273	Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts. <i>Drug Science, Policy and Law</i> , 2020, 6, 205032451990006.	0.6	10
274	Updating the dynamic framework of thought: Creativity and psychedelics. <i>NeuroImage</i> , 2020, 213, 116726.	2.1	57
275	Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects. <i>Journal of Psychoactive Drugs</i> , 2020, 52, 273-281.	1.0	20
276	Investigation of the 2,5-Dimethoxy Motif in Phenethylamine Serotonin 2A Receptor Agonists. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1238-1244.	1.7	11
277	Reviewing the Potential of Psychedelics for the Treatment of PTSD. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 385-400.	1.0	106
278	Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities. <i>Journal of Psychopharmacology</i> , 2020, 34, 612-622.	2.0	36
279	Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models. <i>Frontiers in Neuroscience</i> , 2020, 14, 43.	1.4	29
280	Psilocybin Therapeutic Research: The Present and Future Paradigm. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 399-402.	1.3	24
281	A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT _{2A} receptor binding. <i>European Neuropsychopharmacology</i> , 2020, 33, 71-80.	0.3	88
282	Synthesis and characterization of high-purity N,N-dimethyltryptamine hemifumarate for human clinical trials. <i>Drug Testing and Analysis</i> , 2020, 12, 1483-1493.	1.6	6
283	Direct Phosphorylation of Psilocin Enables Optimized cGMP Kilogram-Scale Manufacture of Psilocybin. <i>ACS Omega</i> , 2020, 5, 16959-16966.	1.6	20
284	Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. <i>Journal of Psychopharmacology</i> , 2020, 34, 1125-1133.	2.0	60

#	ARTICLE	IF	CITATIONS
285	Historic psychedelic drug trials and the treatment of anxiety disorders. <i>Depression and Anxiety</i> , 2020, 37, 1261-1279.	2.0	23
286	Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience. <i>Biomedicines</i> , 2020, 8, 34.	1.4	15
287	Psychedelics and Psychedelic-Assisted Psychotherapy. <i>American Journal of Psychiatry</i> , 2020, 177, 391-410.	4.0	309
288	Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders. <i>Psychopharmacology</i> , 2020, 237, 1521-1532.	1.5	39
289	Emotions and brain function are altered up to one month after a single high dose of psilocybin. <i>Scientific Reports</i> , 2020, 10, 2214.	1.6	169
290	Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. <i>Frontiers in Psychiatry</i> , 2019, 10, 955.	1.3	75
291	Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity. <i>Biological Psychiatry</i> , 2020, 88, 197-207.	0.7	104
292	A dangerous method? Psychedelic therapy at Modum Bad, Norway, 1961-76. <i>History of Psychiatry</i> , 2020, 31, 217-226.	0.1	8
293	Psychedelic Microdosing: Prevalence and Subjective Effects. <i>Journal of Psychoactive Drugs</i> , 2020, 52, 113-122.	1.0	55
294	Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. <i>Journal of Psychopharmacology</i> , 2020, 34, 167-180.	2.0	92
296	Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance. <i>Frontiers in Psychiatry</i> , 2020, 11, 5.	1.3	84
297	Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 2338-2346.	3.3	79
298	A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. <i>Journal of the Neurological Sciences</i> , 2020, 411, 116715.	0.3	52
299	Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects. <i>Journal of Psychedelic Studies</i> , 2020, 4, 114-122.	0.5	14
300	Psychedelics and psychological flexibility – Results of a prospective web-survey using the Acceptance and Action Questionnaire II. <i>Journal of Contextual Behavioral Science</i> , 2020, 16, 37-44.	1.3	28
301	Meditation Increases the Entropy of Brain Oscillatory Activity. <i>Neuroscience</i> , 2020, 431, 40-51.	1.1	49
302	Some Comments on Psychedelic Research. <i>American Journal of Psychiatry</i> , 2020, 177, 368-369.	4.0	10
303	The Viability of Microdosing Psychedelics as a Strategy to Enhance Cognition and Well-being - An Early Review. <i>Journal of Psychoactive Drugs</i> , 2020, 52, 300-308.	1.0	13

#	ARTICLE	IF	CITATIONS
304	Serotonin and serotonin receptors in hallucinogen action. Handbook of Behavioral Neuroscience, 2020, 31, 843-863.	0.7	2
305	Defining the Roles and Research Priorities for Psychedelic-Assisted Therapies in Patients with Serious Illness: Expert Clinicians' and Investigators' Perspectives. Journal of Palliative Medicine, 2020, 23, 1323-1334.	0.6	22
306	Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications. Journal of Music Therapy, 2020, 57, 282-314.	0.6	15
307	Hastened death due to disease burden and distress that has not received timely, quality palliative care is a medical error. Medical Hypotheses, 2020, 142, 109727.	0.8	6
308	Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review. Frontiers in Psychiatry, 2020, 11, 224.	1.3	37
309	Subacute effects of the psychedelic ayahuasca on the salience and default mode networks. Journal of Psychopharmacology, 2020, 34, 623-635.	2.0	52
310	Effects of 5-HT _{2A} receptor stimulation on economic demand for fentanyl after intermittent and continuous access self-administration in male rats. Addiction Biology, 2021, 26, e12926.	1.4	20
311	Psilocybin-Assisted Supportive Psychotherapy in the Treatment of Major Depression—Quo Vadis?. JAMA Psychiatry, 2021, 78, 476.	6.0	3
312	Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 2021, 78, 481.	6.0	648
313	Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin. Journal of Psychopharmacology, 2021, 35, 483-493.	2.0	52
314	New agents and perspectives in the pharmacological treatment of major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 106, 110157.	2.5	13
315	Psychedelic substance use in the Reddit psychonaut community. A qualitative study on motives and modalities. Drugs and Alcohol Today, 2021, 21, 112-123.	0.3	14
316	The Current Status of Psychedelics in Psychiatry. JAMA Psychiatry, 2021, 78, 121.	6.0	116
317	Taking Different Roads: 5-HT _{2A} Receptor as the Origin of Psilocybin Natural Products. ChemPlusChem, 2021, 86, 28-35.	1.3	20
318	Acute subjective effects in LSD- and MDMA-assisted psychotherapy. Journal of Psychopharmacology, 2021, 35, 362-374.	2.0	38
319	Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. Journal of Psychopharmacology, 2021, 35, 459-468.	2.0	40
320	Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice. NeuroImage, 2021, 225, 117456.	2.1	25
321	Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics, 2021, 18, 534-543.	2.1	54

#	ARTICLE	IF	CITATIONS
322	Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 8-21.	1.0	58
323	Psychedelics in Psychiatry—Keeping the Renaissance From Going Off the Rails. <i>JAMA Psychiatry</i> , 2021, 78, 469.	6.0	44
324	Effects of a single dose of psilocybin on behaviour, brain 5-HT _{2A} receptor occupancy and gene expression in the pig. <i>European Neuropsychopharmacology</i> , 2021, 42, 1-11.	0.3	19
325	Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin's main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1164, 122486.	1.2	26
326	MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens. <i>Neuropsychopharmacology</i> , 2021, 46, 545-553.	2.8	21
327	Pivotal mental states. <i>Journal of Psychopharmacology</i> , 2021, 35, 319-352.	2.0	71
328	The bad expert. <i>Social Studies of Science</i> , 2021, 51, 313-338.	1.5	10
329	Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. <i>Journal of Psychopharmacology</i> , 2021, 35, 150-158.	2.0	38
330	Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. <i>Pharmacological Reviews</i> , 2021, 73, 202-277.	7.1	110
331	LSD alters dynamic integration and segregation in the human brain. <i>NeuroImage</i> , 2021, 227, 117653.	2.1	98
332	A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics. <i>Trends in Neurosciences</i> , 2021, 44, 260-275.	4.2	58
333	The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 563-567.	2.5	149
334	The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 568-572.	2.5	223
335	People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. <i>Drugs: Education, Prevention and Policy</i> , 2021, 28, 215-226.	0.8	45
336	Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 101-118.	2.2	137
337	Who is the typical psychedelics user? Methodological challenges for research in psychedelics use and its consequences. <i>NAD Nordic Studies on Alcohol and Drugs</i> , 2021, 38, 35-49.	0.7	11
338	Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. <i>Neuropsychopharmacology</i> , 2021, 46, 537-544.	2.8	120
339	Psychedelic science in post-COVID-19 psychiatry. <i>Irish Journal of Psychological Medicine</i> , 2021, 38, 93-98.	0.7	11

#	ARTICLE	IF	CITATIONS
340	The 5-hydroxytryptamine 2A receptor agonists DOI and 25CN-NBOH decrease marble burying and reverse 8-OH-DPAT-induced deficit in spontaneous alternation. <i>Neuropharmacology</i> , 2021, 183, 107838.	2.0	20
341	The rebirth of psychedelic psychiatry. , 2021, 20, .		0
342	Psychedelic Medicines in Major Depression: Progress and Future Challenges. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1305, 515-533.	0.8	3
343	Microdosing Psychedelics as a Promising New Pharmacotherapeutic. , 2021, , 257-274.		1
344	Optimism and social support as contributing factors to spirituality in Cancer patients. <i>Supportive Care in Cancer</i> , 2021, 29, 3367-3373.	1.0	18
345	Ethnography Of A Novel Remote Use Of An MDA Ceremony. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
346	Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. <i>Scientific Reports</i> , 2021, 11, 1941.	1.6	76
347	Recent Evidence on the Antidepressant Effects of Ayahuasca. , 2021, , 21-41.		8
348	Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD. <i>Journal of Psychopharmacology</i> , 2021, 35, 437-446.	2.0	79
349	Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy. <i>Transcultural Psychiatry</i> , 2022, 59, 652-664.	0.9	61
350	Psychedelics and Psychedelic-Assisted Psychotherapy. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 95-115.	0.4	6
351	Perspectives on Healing and Recovery from Addiction with Ayahuasca-Based Therapy Among Members of an Indigenous Community in Canada. , 2021, , 171-188.		1
352	5-HT2A and 5-HT2C receptors as potential targets for the treatment of nicotine use and dependence. <i>Progress in Brain Research</i> , 2021, 259, 229-263.	0.9	3
353	Entity encounters and the therapeutic effect of the psychedelic mystical experience. <i>Journal of Evolutionary Psychology</i> , 2021, 4, 171-178.	1.4	10
354	Psychedelic Drugs. , 2021, , 1-8.		0
356	The acute effects of classic psychedelics on memory in humans. <i>Psychopharmacology</i> , 2021, 238, 639-653.	1.5	32
357	A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain. <i>International Journal of Molecular Sciences</i> , 2021, 22, 835.	1.8	96
358	Behavioral arrest and a characteristic slow waveform are hallmark responses to selective 5-HT2A receptor activation. <i>Scientific Reports</i> , 2021, 11, 1925.	1.6	9

#	ARTICLE	IF	CITATIONS
359	What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review. <i>Porto Biomedical Journal</i> , 2021, 6, e128.	0.4	15
360	Antidepressant Drugs. , 2021, , .		0
361	Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property. <i>Frontiers in Pharmacology</i> , 2021, 12, 640241.	1.6	31
362	Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. <i>Journal of Psychopharmacology</i> , 2021, 35, 353-361.	2.0	49
364	Update on GPCR-based targets for the development of novel antidepressants. <i>Molecular Psychiatry</i> , 2021, , .	4.1	21
365	Recent developments in geriatric psychopharmacology. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 341-355.	1.3	0
367	Neural and subjective effects of inhaled N,N-dimethyltryptamine in natural settings. <i>Journal of Psychopharmacology</i> , 2021, 35, 406-420.	2.0	29
369	Psychedelic drugs and perception: a narrative review of the first era of research. <i>Reviews in the Neurosciences</i> , 2021, 32, 559-571.	1.4	6
370	Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research. <i>Frontiers in Psychiatry</i> , 2021, 12, 586682.	1.3	38
371	Trends in the Top-Cited Articles on Classic Psychedelics. <i>Journal of Psychoactive Drugs</i> , 2021, 53, 283-298.	1.0	13
373	Dose-response relationships of psilocybin-induced subjective experiences in humans. <i>Journal of Psychopharmacology</i> , 2021, 35, 384-397.	2.0	38
374	Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 416-423.	2.5	31
375	Acute Psychological Adverse Reactions in First-Time Ritual Ayahuasca Users. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 163-171.	0.7	14
376	Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 553-562.	2.5	64
377	Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action. <i>Journal of Psychopharmacology</i> , 2021, 35, 453-458.	2.0	30
378	Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness. <i>Frontiers in Pharmacology</i> , 2021, 12, 623985.	1.6	95
379	The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 901-910.	1.2	31
380	Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 543-552.	2.5	58

#	ARTICLE	IF	CITATIONS
381	A qualitative and quantitative account of patient's experiences of ketamine and its antidepressant properties. <i>Journal of Psychopharmacology</i> , 2021, 35, 946-961.	2.0	32
382	LSD et soins palliatifs dans les années 1960, un rendez-vous manqué? <i>Medecine Palliative</i> , 2021, 20, 312-312.	0.0	1
383	What cancer research makes the news? A quantitative analysis of online news stories that mention cancer studies. <i>PLoS ONE</i> , 2021, 16, e0247553.	1.1	7
384	On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 436-451.	2.5	22
385	Chemoenzymatic Synthesis of 5-Methylpsilocybin: A Tryptamine with Potential Psychedelic Activity. <i>Journal of Natural Products</i> , 2021, 84, 1403-1408.	1.5	7
386	Cannabis-induced oceanic boundlessness. <i>Journal of Psychopharmacology</i> , 2021, 35, 841-847.	2.0	17
387	Identification of the Antidepressant Function of the Edible Mushroom <i>Pleurotus eryngii</i> . <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 190.	1.5	7
388	Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016–2020) systematic review of preclinical and human studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 541-556.	1.8	21
389	Entheogens and psychedelics in Canada: Proposal for a new paradigm.. <i>Canadian Psychology</i> , 2022, 63, 413-430.	1.4	11
390	Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment. <i>Drugs: Education, Prevention and Policy</i> , 2021, 28, 211-214.	0.8	23
391	MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers. <i>Trials</i> , 2021, 22, 302.	0.7	8
392	Effectiveness of Psilocybin on Depression: A Qualitative Study. <i>Electronic Journal of General Medicine</i> , 2021, 18, em296.	0.3	5
393	Ethical and legal issues in psychedelic harm reduction and integration therapy. <i>Harm Reduction Journal</i> , 2021, 18, 40.	1.3	41
394	Psilocybin and MDMA for the treatment of trauma-related psychopathology. <i>International Review of Psychiatry</i> , 2021, 33, 229-249.	1.4	46
395	From "molecules of life" to new therapeutic approaches, an evolution marked by the advent of artificial intelligence: the cases of chronic pain and neuropathic disorders. <i>Drug Discovery Today</i> , 2021, 26, 1070-1075.	3.2	1
396	Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?. <i>Journal of Psychopharmacology</i> , 2022, 36, 6-11.	2.0	28
397	Psilocybin: From Serendipity to Credibility?. <i>Frontiers in Psychiatry</i> , 2021, 12, 659044.	1.3	20
399	Mapping an Agenda for Psychedelic-Assisted Therapy Research in Patients with Serious Illness. <i>Journal of Palliative Medicine</i> , 2021, 24, 1657-1666.	0.6	14

#	ARTICLE	IF	CITATIONS
400	Trial of Psilocybin versus Escitalopram for Depression. <i>New England Journal of Medicine</i> , 2021, 384, 1402-1411.	13.9	643
401	Letter to the editor: Are ketamine-induced subjective bodily experiences associated with antidepressant effects? A sensation of floating and a sensation of lightness are not the same – A comment on Acevedo-Díaz et al. <i>Journal of Psychiatric Research</i> , 2021, 137, 454-455.	1.5	0
402	Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. <i>Journal of Psychiatric Research</i> , 2021, 137, 273-282.	1.5	41
403	Psychedelics and health behaviour change. <i>Journal of Psychopharmacology</i> , 2022, 36, 12-19.	2.0	40
404	Day trip to hell: A mixed methods study of challenging psychedelic experiences. <i>Journal of Psychedelic Studies</i> , 2021, 5, 114-127.	0.5	17
405	Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center. <i>Frontiers in Pharmacology</i> , 2021, 12, 659644.	1.6	11
406	Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis. <i>Scientific Reports</i> , 2021, 11, 10851.	1.6	20
407	The Therapeutic Potential of Psilocybin. <i>Molecules</i> , 2021, 26, 2948.	1.7	78
408	Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 615-623.	1.0	20
409	An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress. <i>Molecular Psychiatry</i> , 2021, 26, 6237-6252.	4.1	39
410	Four individuals' experiences during and following a psilocybin truffle retreat in the Netherlands. <i>Journal of Psychedelic Studies</i> , 2021, 5, 22-32.	0.5	6
411	Exploring the relationship between microdosing, personality and emotional insight: A prospective study. <i>Journal of Psychedelic Studies</i> , 2021, 5, 9-16.	0.5	6
412	Psychedelics as Reemerging Treatments for Anxiety Disorders: Possibilities and Challenges in a Nascent Field. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 190-196.	0.4	2
414	CE: Psychedelic-Assisted Therapy. <i>American Journal of Nursing</i> , 2021, 121, 34-40.	0.2	15
415	Ayahuasca Improves Self-perception of Speech Performance in Subjects With Social Anxiety Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 540-550.	0.7	42
416	Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. <i>Journal of Psychopharmacology</i> , 2022, 36, 74-84.	2.0	29
418	An Improved, Scalable Synthesis of the Selective Serotonin 2A Receptor Agonist 25CN-NBOH. <i>SynOpen</i> , 2021, 05, 158-160.	0.8	2
419	Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 444-454.	1.1	18

#	ARTICLE	IF	CITATIONS
420	Early LSD treatment in Denmark from 1960 to 1974. <i>Medicine (United States)</i> , 2021, 100, e26300.	0.4	3
422	Psychedelics as a Training Experience for Psychedelic Therapists: Drawing on History to Inform Current Practice. <i>Journal of Humanistic Psychology</i> , 0, , 002216782110212.	1.4	16
423	Catalysts for change: the cellular neurobiology of psychedelics. <i>Molecular Biology of the Cell</i> , 2021, 32, 1135-1144.	0.9	21
424	Palliative care: is it time for health professionals to talk openly about psychedelic therapy?. <i>British Journal of General Practice</i> , 2021, 71, 318-319.	0.7	0
425	LSD use in the United States: Trends, correlates, and a typology of us. <i>Drug and Alcohol Dependence</i> , 2021, 223, 108715.	1.6	30
426	A Nationwide Study Comparing Mental Health Professionals's Willingness to Try Hallucinogenic Drugs in Basic Research or Clinical Practice. <i>Journal of Psychoactive Drugs</i> , 2021, , 1-11.	1.0	1
427	Exploring the Use of Psilocybin Therapy for Existential Distress: A Qualitative Study of Palliative Care Provider Perceptions. <i>Journal of Psychoactive Drugs</i> , 2022, 54, 81-92.	1.0	5
428	Racial/ethnic differences in prevalence of hallucinogen use by age cohort: Findings from the 2018 National Survey on Drug Use and Health. <i>Journal of Psychedelic Studies</i> , 2021, 5, 69-82.	0.5	18
429	Turn on, Tune in, and Drop out: Predictors of Attrition in a Prospective Observational Cohort Study on Psychedelic Use. <i>Journal of Medical Internet Research</i> , 2021, 23, e25973.	2.1	10
430	Psychedelic drug use and schizotypy in young adults. <i>Scientific Reports</i> , 2021, 11, 15058.	1.6	8
431	Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy. <i>American Journal of Psychotherapy</i> , 2021, 74, 140-149.	0.4	46
432	The Ethic of Access: An AIDS Activist Won Public Access to Experimental Therapies, and This Must Now Extend to Psychedelics for Mental Illness. <i>Frontiers in Psychiatry</i> , 2021, 12, 680626.	1.3	6
433	Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer. <i>Journal of the Academy of Consultation-Liaison Psychiatry</i> , 2021, 62, 460-471.	0.2	7
434	Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy. <i>Frontiers in Psychology</i> , 2021, 12, 617224.	1.1	28
436	Losing the Self in Near-Death Experiences: The Experience of Ego-Dissolution. <i>Brain Sciences</i> , 2021, 11, 929.	1.1	14
437	Re-Examining Death: Doors to Resilience and Wellbeing in Tibetan Buddhist Practice. <i>Religions</i> , 2021, 12, 522.	0.3	3
438	Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?. <i>Frontiers in Psychiatry</i> , 2021, 12, 661233.	1.3	41
439	The Potential Role of Serotonergic Hallucinogens in Depression Treatment. <i>Life</i> , 2021, 11, 765.	1.1	6

#	ARTICLE	IF	CITATIONS
440	LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model. <i>Psychological Medicine</i> , 2023, 53, 1151-1165.	2.7	20
442	Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. <i>Pharmaceuticals</i> , 2021, 14, 793.	1.7	13
443	Intersection of Racism and PTSD: Assessment and Treatment of Racial Stress and Trauma. <i>Current Treatment Options in Psychiatry</i> , 2021, 8, 167-185.	0.7	22
444	Depression as a Disorder of Consciousness. <i>British Journal for the Philosophy of Science</i> , 0, , .	1.4	6
445	Blinding and expectancy confounds in psychedelic randomized controlled trials. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1133-1152.	1.3	133
446	25CNâ€”BOH: A Selective Agonist for inâ€”vitro and inâ€”vivo Investigations of the Serotonin 2A Receptor. <i>ChemMedChem</i> , 2021, 16, 3263-3270.	1.6	8
447	Pharmacologic Similarities and Differences Among Hallucinogens. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S100-S113.	1.0	4
448	Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports. <i>Pharmacopsychiatry</i> , 2021, 54, 240-245.	1.7	29
449	Cancer Healthcare Workersâ€™ Perceptions toward Psychedelic-Assisted Therapy: A Preliminary Investigation. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8160.	1.2	6
450	Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy. <i>Frontiers in Psychiatry</i> , 2021, 12, 707057.	1.3	20
451	Psilocybin for Depression. <i>New England Journal of Medicine</i> , 2021, 385, 862-864.	13.9	5
452	PossÃvel uso da Psilocibina no tratamento psiquiÃtrico, incluindo sequelas da COVID-19. <i>Research, Society and Development</i> , 2021, 10, e49101119259.	0.0	0
453	Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex inÃvivo. <i>Neuron</i> , 2021, 109, 2535-2544.e4.	3.8	214
454	Use of alternative therapy with Psilocybin in oncologic patients with depression and/or anxiety disorders - integrative review. <i>Research, Society and Development</i> , 2021, 10, e568101019297.	0.0	0
455	Spontaneous Spiritual Awakenings: Phenomenology, Altered States, Individual Differences, and Well-Being. <i>Frontiers in Psychology</i> , 2021, 12, 720579.	1.1	20
456	Psychologically Informed Palliative Care and Beyond. <i>Journal of Palliative Medicine</i> , 2021, 24, 1266-1267.	0.6	0
457	The Role of Psilocybin-Assisted Psychotherapy to Support Patients With Cancer: A Critical Scoping Review of the Research. <i>Journal of Holistic Nursing</i> , 2021, , 089801012110390.	0.6	3
458	From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders. <i>Journal of Neurochemistry</i> , 2022, 162, 89-108.	2.1	27

#	ARTICLE	IF	CITATIONS
459	Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. <i>Journal of Psychopharmacology</i> , 2022, 36, 20-30.	2.0	19
460	Evaluating the risk of psilocybin for the treatment of bipolar depression: A review of the research literature and published case studies. <i>Journal of Affective Disorders Reports</i> , 2021, 6, 100240.	0.9	13
461	Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach. <i>Neurobiology of Learning and Memory</i> , 2021, 183, 107467.	1.0	20
462	Ancient Roots of Today's Emerging Renaissance in Psychedelic Medicine. <i>Culture, Medicine and Psychiatry</i> , 2022, 46, 890-903.	0.7	11
463	A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production.. <i>F1000Research</i> , 0, 10, 961.	0.8	6
464	A Qualitative Exploration of Relational Ethical Challenges and Practices in Psychedelic Healing. <i>Journal of Humanistic Psychology</i> , 0, , 002216782110452.	1.4	22
465	Rediscovering Psilocybin as an Antidepressive Treatment Strategy. <i>Pharmaceuticals</i> , 2021, 14, 985.	1.7	8
466	The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies. <i>Frontiers in Pharmacology</i> , 2021, 12, 739053.	1.6	11
467	Co-design of Guidance for Patient and Public Involvement in Psychedelic Research. <i>Frontiers in Psychiatry</i> , 2021, 12, 727496.	1.3	8
468	Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. <i>European Neuropsychopharmacology</i> , 2021, 50, 121-132.	0.3	57
469	Safety pharmacology of acute LSD administration in healthy subjects. <i>Psychopharmacology</i> , 2022, 239, 1893-1905.	1.5	18
470	Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems. <i>Frontiers in Psychiatry</i> , 2021, 12, 716593.	1.3	5
471	Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. <i>Journal of Psychoactive Drugs</i> , 2022, 54, 309-318.	1.0	26
472	New Insights Into the Clinical and Nonclinical Effects of Psychedelic Substances. <i>European Psychologist</i> , 0, , .	1.8	1
473	Narrative Review: Bioactive Potential of Various Mushrooms as the Treasure of Versatile Therapeutic Natural Product. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 728.	1.5	24
474	Persisting Effects of Ayahuasca on Empathy, Creative Thinking, Decentering, Personality, and Well-Being. <i>Frontiers in Pharmacology</i> , 2021, 12, 721537.	1.6	24
475	Enhancing equity-oriented care in psychedelic medicine: Utilizing the EQUIP framework. <i>International Journal of Drug Policy</i> , 2021, 98, 103429.	1.6	8
476	Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. <i>International Journal of Drug Policy</i> , 2021, 98, 103380.	1.6	21

#	ARTICLE	IF	CITATIONS
477	Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2022, 296, 26-34.	2.0	29
478	Psychedelic Medicines: A Paradigm Shift from Pharmacological Substitution Towards Transformation-Based Psychiatry. , 2021, , 43-61.		5
479	Classical Psychedelics as Therapeutics in Psychiatry – Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders. <i>Pharmacopsychiatry</i> , 2021, 54, 176-190.	1.7	34
480	Pharmacological assistance for psychotherapy. <i>Emerging Trends in Drugs, Addictions, and Health</i> , 2021, 1, 100017.	0.5	0
481	Cortical influences of serotonin and glutamate on layer V pyramidal neurons. <i>Progress in Brain Research</i> , 2021, 261, 341-378.	0.9	7
482	Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color. <i>Chronic Stress</i> , 2021, 5, 247054702110356.	1.7	19
483	Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. <i>Psychopharmacology</i> , 2021, 238, 341-354.	1.5	70
484	Potential Anti-Depressive Treatment Maneuvers from Bench to Bedside. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1180, 277-295.	0.8	3
485	The top ten things that must be known about end of life therapy in patients with advanced cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 88-92.	0.3	2
486	Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. <i>NeuroImage</i> , 2020, 218, 116980.	2.1	92
487	Discriminative Stimulus Effects of Substituted Tryptamines in Rats. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 467-471.	2.5	7
488	Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 472-478.	2.5	51
489	Effects of acute and repeated treatment with serotonin 5-HT _{2A} receptor agonist hallucinogens on intracranial self-stimulation in rats.. <i>Experimental and Clinical Psychopharmacology</i> , 2019, 27, 215-226.	1.3	32
490	Psychedelics and Psychotherapy. <i>Pharmacopsychiatry</i> , 2021, 54, 167-175.	1.7	35
499	Effects of psilocybin therapy on personality structure. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 368-378.	2.2	156
500	International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. <i>Pharmacological Reviews</i> , 2021, 73, 310-520.	7.1	127
501	Isness: Using Multi-Person VR to Design Peak Mystical Type Experiences Comparable to Psychedelics. , 2020, , .		24
502	Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis. <i>Journal of Psychopharmacology</i> , 2020, 34, 1079-1085.	2.0	52

#	ARTICLE	IF	CITATIONS
503	Rapid-Acting Antidepressants. <i>Current Pharmaceutical Design</i> , 2018, 24, 2556-2563.	0.9	36
504	Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications. <i>Current Neuropharmacology</i> , 2017, 15, 1032-1042.	1.4	43
505	Hallucinogen Use in College Students: Current Trends and Consequences of Use. <i>Current Psychopharmacology</i> , 2020, 9, 115-127.	0.1	2
506	Emerging Psychedelic-Assisted Therapies: Implications for Nursing Practice. <i>Journal of Mental Health and Addiction Nursing</i> , 2020, 4, e1-e13.	2.6	5
507	Psychedelic drugsâ€”a new era inâ€”psychiatry?. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 139-147.	1.8	70
508	Compassion-Focused Therapy on Levels of Anxiety and Depression Among Women with Breast Cancer; A Randomized Pilot Trial. <i>International Journal of Cancer Management</i> , 2018, In Press, .	0.2	15
509	Models of psychedelic drug action: modulation of cortical-subcortical circuits. <i>Brain</i> , 2022, 145, 441-456.	3.7	82
510	Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?. <i>Bioengineered</i> , 2021, 12, 8863-8871.	1.4	2
511	Psychological Antecedents to the Effects of Psychedelics on Workplace Productivity: Interview Evidence of a Naturalistic Setting. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
512	Schedule 1 barriersâ€”to research in the UK: An in-depth qualitative analysis. <i>Drug Science, Policy and Law</i> , 2021, 7, 205032452110493.	0.6	3
513	Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. <i>Cell Reports</i> , 2021, 37, 109836.	2.9	82
514	Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis. <i>Psychiatry Investigation</i> , 2021, 18, 958-967.	0.7	13
515	Study Protocol for â€”Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Studyâ€”. <i>Frontiers in Psychiatry</i> , 2021, 12, 735523.	1.3	33
516	Psychedelics and Other Psychoplastogens for Treating Mental Illness. <i>Frontiers in Psychiatry</i> , 2021, 12, 727117.	1.3	70
517	Classic Psychedelic Use and Mechanisms of Mental Health: Exploring the Mediating Roles of Spirituality and Emotion Processing on Symptoms of Anxiety, Depressed Mood, and Disordered Eating in a Community Sample. <i>Journal of Humanistic Psychology</i> , 0, , 002216782110480.	1.4	12
518	Psychedelic therapy: a roadmap for wider acceptance and utilization. <i>Nature Medicine</i> , 2021, 27, 1669-1671.	15.2	25
519	Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults. <i>Psychopharmacology</i> , 2022, 239, 1735-1747.	1.5	33
521	Psychedelika. , 2017, , 1-19.		0

#	ARTICLE	IF	CITATIONS
523	Psychedelika. , 2018, , 669-682.		0
524	The role of the pharmaceutical industry in the treatment of mental health disorders.. , 2019, , 673-687.		0
525	Traitements psychopharmacologiques. , 2019, , 581-613.		0
530	A potential role for psilocybin in the treatment of obsessive-compulsive disorder. Journal of Psychedelic Studies, 2020, 4, 77-87.	0.5	2
533	Carl Jung and the Psychedelic Brain. International Journal of Jungian Studies, 2021, 14, 97-126.	0.2	0
534	A narrative synthesis of research with 5-MeO-DMT. Journal of Psychopharmacology, 2022, 36, 273-294.	2.0	28
535	Innovation at life's end: a moment for hope. Annals of Oncology, 2022, 33, 15-16.	0.6	0
536	Hallucinogens as Therapeutic Agents: Past, Present, and Future. , 2021, , 1-12.		0
537	Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting. International Journal of Drug Policy, 2022, 100, 103518.	1.6	10
538	11 New Avenues Toward Drug Discovery in Fungi. , 2020, , 267-295.		0
539	Medicinal Mushrooms. , 2020, , 679-692.e6.		0
540	Gut Microbiome and Its Role in Enteric Infections with Microbial Pathogens. , 2020, , 187-208.		0
541	Psychedelic Drugs and Jungian Therapy. Journal of Jungian Scholarly Studies, 2020, 15, 86-98.	0.0	2
542	Molecular targets of psychedelic-induced plasticity. Journal of Neurochemistry, 2022, 162, 80-88.	2.1	15
543	The potential role of lysergic acid diethylamide for psychological assisted therapy: A meta-analysis of randomised controlled trials in healthy volunteers. Human Psychopharmacology, 2022, 37, e2825.	0.7	4
544	Lysergic acid diethylamide induces increased signalling entropy in rats' prefrontal cortex. Journal of Neurochemistry, 2022, 162, 9-23.	2.1	6
545	Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Clinical Pharmacology and Therapeutics, 2022, 111, 886-895.	2.3	70
546	Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translational Psychiatry, 2021, 11, 574.	2.4	115

#	ARTICLE	IF	CITATIONS
547	Baseline Power of Theta Oscillations Predicts Mystical-Type Experiences Induced by DMT in a Natural Setting. <i>Frontiers in Psychiatry</i> , 2021, 12, 720066.	1.3	9
548	Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey. <i>Psychopharmacology</i> , 2022, 239, 1425-1440.	1.5	13
549	The Role of Psychedelics and Counseling in Mental Health Treatment. <i>Journal of Mental Health Counseling</i> , 2020, 42, 323-338.	0.6	18
554	Communalistic use of psychoactive plants as a bridge between traditional healing practices and Western medicine: A new path for the Global Mental Health movement. <i>Transcultural Psychiatry</i> , 2022, 59, 638-651.	0.9	10
555	Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors. <i>Pharmaceuticals</i> , 2021, 14, 1213.	1.7	15
556	Self-Medication for Chronic Pain Using Classic Psychedelics: A Qualitative Investigation to Inform Future Research. <i>Frontiers in Psychiatry</i> , 2021, 12, 735427.	1.3	15
557	The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy. <i>Frontiers in Psychiatry</i> , 2021, 12, .	1.3	9
558	Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy. <i>Current Addiction Reports</i> , 2022, 9, 48-58.	1.6	7
559	Examining Psychedelic-Induced Changes in Social Functioning and Connectedness in a Naturalistic Online Sample Using the Five-Factor Model of Personality. <i>Frontiers in Psychology</i> , 2021, 12, 749788.	1.1	13
561	Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. <i>Psychopharmacology</i> , 2022, 239, 15-33.	1.5	45
562	A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,ÅN-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers. <i>Frontiers in Pharmacology</i> , 2021, 12, 760671.	1.6	20
563	A Semantic Scale Network analysis of the revised Mystical Experiences Questionnaire: A call for collaboration. <i>Journal of Psychedelic Studies</i> , 2021, , .	0.5	1
564	Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial. <i>BMJ Open</i> , 2021, 11, e056091.	0.8	7
565	Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 1250-1260.	1.0	3
566	Psychedelic Drugs. , 2021, , 1313-1320.		0
567	Neuroinflammatory remodeling of the anterior cingulate cortex as a key driver of mood disorders in gastrointestinal disease and disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 133, 104497.	2.9	25
568	Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120096.	0.3	10
569	The Potential of Psychedelics for End of Life and Palliative Care. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 169-184.	0.8	8

#	ARTICLE	IF	CITATIONS
570	Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 187-211.	0.8	8
571	Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 1.	0.8	2
572	Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 287-317.	0.8	11
573	Dosing Psychedelics and MDMA. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 3-21.	0.8	12
574	Ayahuasca for the Treatment of Depression. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 113-124.	0.8	6
575	Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry. <i>Pharmacopsychiatry</i> , 2022, 55, 193-202.	1.7	12
576	The therapeutic potential of psychedelic substances in Hospice and Palliative Care. <i>Progress in Palliative Care</i> , 2022, 30, 1-3.	0.7	4
578	Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder. <i>Journal of the Neurological Sciences</i> , 2022, 432, 120094.	0.3	6
579	Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. <i>Psychopharmacology</i> , 2022, 239, 1907-1932.	1.5	36
580	Acute sleep deprivation upregulates serotonin 2A receptors in the frontal cortex of mice via the immediate early gene <i>Egr3</i> . <i>Molecular Psychiatry</i> , 2022, 27, 1599-1610.	4.1	8
581	Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. <i>Journal of Psychopharmacology</i> , 2022, 36, 57-65.	2.0	22
582	Psychedelics hold promise for primary care research. <i>Family Practice</i> , 2022, , .	0.8	0
583	The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 1-10.	1.0	22
584	Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples. <i>Acta Crystallographica Section C, Structural Chemistry</i> , 2022, 78, 36-55.	0.2	7
585	Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 73-84.	1.0	7
586	MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. <i>Journal of Psychopharmacology</i> , 2022, 36, 46-56.	2.0	28
587	The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. <i>Journal of Psychopharmacology</i> , 2022, 36, 114-125.	2.0	47
588	Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder. <i>Frontiers in Pharmacology</i> , 2021, 12, 749068.	1.6	16

#	ARTICLE	IF	CITATIONS
589	Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity. <i>Biochemistry</i> , 2022, 61, 127-136.	1.2	41
590	Effects of Psychedelic Use on Racial Trauma Symptoms and Ethnic Identity among Asians in North America. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 19-29.	1.0	8
591	Exploring the Credibility of Psilocybin-assisted Therapy and Cognitive-behavioral Therapy for Depression. <i>Journal of Psychoactive Drugs</i> , 2022, 54, 462-470.	1.0	1
592	Classic Psychedelic Drugs: Update on Biological Mechanisms. <i>Pharmacopsychiatry</i> , 2022, 55, 121-138.	1.7	34
593	Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation. <i>Frontiers in Neuroergonomics</i> , 2022, 2, .	0.6	4
594	Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension. <i>Journal of Psychopharmacology</i> , 2022, 36, 66-73.	2.0	16
595	Structure-based discovery of nonhallucinogenic psychedelic analogs. <i>Science</i> , 2022, 375, 403-411.	6.0	126
596	Philosophy and classic psychedelics: A review of some emerging themes. <i>Journal of Psychedelic Studies</i> , 2022, 5, 166-175.	0.5	4
597	An experience with Holotropic Breathwork is associated with improvement in non-judgement and satisfaction with life while reducing symptoms of stress in a Czech-speaking population. <i>Journal of Psychedelic Studies</i> , 2022, 5, 176-189.	0.5	2
600	Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?. <i>Journal of Xenobiotics</i> , 2022, 12, 41-52.	2.9	10
601	The Therapeutic Potential of Psychedelic-assisted Therapies for Symptom Control in Patients Diagnosed With Serious Illness: A Systematic Review. <i>Journal of Pain and Symptom Management</i> , 2022, 63, e725-e738.	0.6	15
602	Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development. <i>Fungal Biology</i> , 2022, 126, 308-319.	1.1	32
603	The frontiers of new psychedelic therapies: A survey of sociological themes and issues. <i>Sociology Compass</i> , 2022, 16, .	1.4	9
604	Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review. <i>Cureus</i> , 2022, 14, e21944.	0.2	3
605	The clinical pharmacology and potential therapeutic applications of 5- <i>N,N</i> -dimethyltryptamine (5-MeO-DMT). <i>Journal of Neurochemistry</i> , 2022, 162, 128-146.	2.1	31
606	Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective. <i>Frontiers in Psychiatry</i> , 2021, 12, 800072.	1.3	35
607	A potential effect of psilocybin on anxiety in neurotic personality structures in adolescents. <i>Croatian Medical Journal</i> , 2021, 62, 528-530.	0.2	0
608	Psychedelic Psychotherapy: Building Wholeness Through Connection. <i>Global Advances in Health and Medicine</i> , 2022, 11, 2164957X2210811.	0.7	8

#	ARTICLE	IF	CITATIONS
609	Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – Rationale and study design. , 2022, 1, 100104.		12
610	Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials. <i>Drug Science, Policy and Law</i> , 2022, 8, 205032452210852.	0.6	16
611	Human behavioral pharmacology of psychedelics. <i>Advances in Pharmacology</i> , 2022, 93, 105-132.	1.2	6
612	Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. <i>Journal of Psychopharmacology</i> , 2022, 36, 151-158.	2.0	162
613	Hallucinogenic drugs and their potential for treating fear-related disorders: Through the lens of fear extinction. <i>Journal of Neuroscience Research</i> , 2022, 100, 947-969.	1.3	8
614	The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 40-50.	1.0	29
615	Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 938.	1.0	17
617	Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. <i>Neuropsychopharmacology</i> , 2022, 47, 1180-1187.	2.8	72
618	Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil. <i>Psychopharmacology</i> , 2022, 239, 1767-1782.	1.5	8
619	Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy. <i>Frontiers in Psychology</i> , 2022, 13, 813746.	1.1	9
620	How Important Is a Guide Who Has Taken Psilocybin in Psilocybin-Assisted Therapy for Depression?. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 51-61.	1.0	16
621	Predictors and potentiators of psychedelic-occasioned mystical experiences. <i>Journal of Psychedelic Studies</i> , 2022, 6, 31-47.	0.5	4
622	The promises and perils of psychedelic pharmacology for psychiatry. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 463-473.	21.5	82
623	Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer. <i>Current Treatment Options in Oncology</i> , 2022, 23, 348-358.	1.3	6
624	Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca. <i>Journal of Psychopharmacology</i> , 2022, 36, 295-308.	2.0	19
625	The therapeutic potential of psilocybin: a systematic review. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 833-840.	1.0	14
627	Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats. <i>Psychopharmacology</i> , 2022, 239, 1689-1703.	1.5	13
628	Language as a Window Into the Altered State of Consciousness Elicited by Psychedelic Drugs. <i>Frontiers in Pharmacology</i> , 2022, 13, 812227.	1.6	4

#	ARTICLE	IF	CITATIONS
629	The role of serotonin neurotransmission in rapid antidepressant actions. <i>Psychopharmacology</i> , 2022, 239, 1823-1838.	1.5	9
630	Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline. <i>Neuropsychopharmacology</i> , 2022, 47, 1188-1198.	2.8	36
631	Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations. <i>Transcultural Psychiatry</i> , 2022, 59, 691-704.	0.9	35
632	Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness. <i>Journal of Palliative Medicine</i> , 2022, 25, 1273-1281.	0.6	8
633	The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs' effects on psychological flexibility. <i>Journal of Psychopharmacology</i> , 2022, 36, 387-408.	2.0	19
634	How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework. <i>Psychopharmacology</i> , 2022, 239, 1853-1879.	1.5	5
635	Magic Mushroom Use: A Qualitative Interview Study of Post-Trip Impacts and Strategies for Optimizing Experiences. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 151-158.	1.0	4
637	Effects of the 5-HT _{2A} receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents. <i>Psychopharmacology</i> , 2022, 239, 1665-1677.	1.5	16
638	Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 290.	1.5	8
639	Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States. <i>Frontiers in Psychiatry</i> , 2022, 13, 831092.	1.3	20
640	Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms. <i>Current Reviews in Clinical and Experimental Pharmacology</i> , 2023, 18, 94-109.	0.4	1
641	Psilocybin-Assisted Compassion Focused Therapy for Depression. <i>Frontiers in Psychology</i> , 2022, 13, 812930.	1.1	19
642	Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression. <i>Frontiers in Pharmacology</i> , 2021, 12, 788155.	1.6	77
643	Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report. <i>Frontiers in Pharmacology</i> , 2022, 13, 841648.	1.6	29
644	A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders. <i>Australian and New Zealand Journal of Psychiatry</i> , 2023, 57, 362-378.	1.3	12
645	A Single Belief-Changing Psychedelic Experience Is Associated With Increased Attribution of Consciousness to Living and Non-living Entities. <i>Frontiers in Psychology</i> , 2022, 13, 852248.	1.1	30
646	Charismatic, Synchronous and Psychedelic Religious Experiences: A Personal Account. <i>Religions</i> , 2022, 13, 331.	0.3	0
647	Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. <i>Psychopharmacology</i> , 2022, 239, 1989-2010.	1.5	70

#	ARTICLE	IF	CITATIONS
648	Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?. Expert Opinion on Drug Safety, 2022, , 1-4.	1.0	2
651	Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada. , 2022, 3, 100044.		1
652	Toward a positive psychology of psychoactive drug use. Drugs: Education, Prevention and Policy, 2023, 30, 81-94.	0.8	1
653	Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies. BMC Palliative Care, 2021, 20, 191.	0.8	10
654	P.0729 Highlights of psychedelic history and current research on psilocybin application for treatment of depression â€” a comprehensive literature review. European Neuropsychopharmacology, 2021, 53, S532-S533.	0.3	1
656	P.0353 Study protocol: psilocybin as a treatment for anorexia nervosa: a pilot study. European Neuropsychopharmacology, 2021, 53, S257-S258.	0.3	0
657	A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production.. F1000Research, 0, 10, 961.	0.8	0
658	1H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids?. Frontiers in Psychiatry, 2021, 12, 742856.	1.3	0
660	Effects of classic psychedelic drugs on turbulent signatures in brain dynamics. Network Neuroscience, 2022, 6, 1104-1124.	1.4	10
661	Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. Expert Opinion on Drug Safety, 2022, 21, 761-776.	1.0	13
686	Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice. Neuropsychopharmacology, 2022, 47, 1304-1314.	2.8	14
687	Classical hallucinogens as antidepressant drugs: A cautionary approach. Current Neuropharmacology, 2022, 20, .	1.4	0
688	Toward Synergies of Ketamine and Psychotherapy. Frontiers in Psychology, 2022, 13, 868103.	1.1	18
689	Virtual Reality and Psychedelics for the Treatment of Psychiatric Disease: A Systematic Literature Review.. , 2020, 17, 365-380.		4
690	Will psilocybin lose its magic in the clinical setting?. Therapeutic Advances in Psychopharmacology, 2022, 12, 204512532210908.	1.2	7
691	Psychedelics and Anti-inflammatory Activity in Animal Models. Current Topics in Behavioral Neurosciences, 2022, , 229-245.	0.8	6
692	Psychedelics in the Treatment of Headache and Chronic Pain Disorders. Current Topics in Behavioral Neurosciences, 2022, , 261-285.	0.8	5
693	Conformational Analysis of Psilocybin: A Computational Approach. SSRN Electronic Journal, 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
694	Ministry of the Mushroom. <i>International Journal for the Study of New Religions</i> , 2022, 11, .	0.0	1
696	Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences. <i>Journal of Psychopharmacology</i> , 2022, 36, 987-1000.	2.0	11
697	Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders. <i>Frontiers in Psychiatry</i> , 2022, 13, 863552.	1.3	21
699	The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies. <i>Psychiatry Research</i> , 2022, 313, 114577.	1.7	2
701	The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice. <i>Journal of Midwifery and Women's Health</i> , 2022, 67, 373-383.	0.7	2
702	Toward a New Science of Psychedelic Social Psychology: The Effects of MDMA (Ecstasy) on Social Connection. <i>Perspectives on Psychological Science</i> , 2022, 17, 1234-1257.	5.2	7
703	Do psychedelics change beliefs?. <i>Psychopharmacology</i> , 2022, 239, 1809-1821.	1.5	7
704	The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol. <i>Systematic Reviews</i> , 2022, 11, 85.	2.5	2
705	Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review. <i>Psychiatry Research</i> , 2022, 312, 114579.	1.7	5
706	Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex. <i>NeuroImage</i> , 2022, 256, 119220.	2.1	39
707	Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation. , 2022, 239, 108195.		20
708	Self-Care Practices with Psychedelics – A Qualitative Study of Users’ Perspectives. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 159-169.	1.0	3
709	The efficacy of psilocybin in the treatment of depression and anxiety: A meta-analysis. <i>Current Psychiatry Research and Reviews</i> , 2022, 18, .	0.1	0
710	Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 138, 104689.	2.9	45
711	Genetic Survey of <i>Psilocybe</i> Natural Products. <i>ChemBioChem</i> , 2022, 23, .	1.3	16
712	The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences. <i>Frontiers in Psychology</i> , 2022, 13, .	1.1	5
713	If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics. <i>Journal of Pain</i> , 2022, 23, 1666-1679.	0.7	8
714	The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 139, 104706.	2.9	34

#	ARTICLE	IF	CITATIONS
715	Postpartum depression: A role for psychedelics?. Journal of Psychopharmacology, 2022, 36, 920-931.	2.0	2
716	Unraveling the Mysteries of Mental Illness With Psilocybin. Cureus, 2022, , .	0.2	1
717	Systematic Review of Psychometric Instruments Used in Research with Psychedelics. Journal of Psychoactive Drugs, 2023, 55, 359-368.	1.0	10
718	Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default. Frontiers in Psychology, 2022, 13, .	1.1	41
719	Psychoactive Drugs in the Management of Post Traumatic Stress Disorder: A Promising New Horizon. Cureus, 2022, , .	0.2	1
720	Group VR experiences can produce ego attenuation and connectedness comparable to psychedelics. Scientific Reports, 2022, 12, .	1.6	11
721	Pruning recurrent neural networks replicates adolescent changes in working memory and reinforcement learning. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	13
722	Trust and Psychedelic Moral Enhancement. Neuroethics, 2022, 15, .	1.7	1
723	Review of otential sychedelic reatments for PTSD. Journal of the Neurological Sciences, 2022, 439, 120302.	0.3	10
724	uso de psicodÃ©licos como acesso Ã consciÃªncia primÃ¡ria e sua relaÃ§Ã£o com a teoria dos arquÃ©tipos. Self - Revista Do Instituto Junguiano De SÃ£o Paulo, 2022, 7, e04.	0.0	0
725	Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model. Frontiers in Psychology, 2022, 13, .	1.1	24
726	Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology, 2022, 47, 1854-1862.	2.8	64
727	Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation. Current Topics in Behavioral Neurosciences, 2022, , 213-227.	0.8	10
728	Should Adolescents be Included in Emerging Psychedelic Research?. Canadian Journal of Bioethics, 2022, 5, 36.	0.0	2
729	Neural mechanisms underlying psilocybinâ€™s therapeutic potential â€“ the need for preclinical in vivo electrophysiology. Journal of Psychopharmacology, 2022, 36, 781-793.	2.0	13
730	Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study. Journal of Psychoactive Drugs, 2023, 55, 310-320.	1.0	3
731	Investigational Drugs for the Treatment of Depression (Part 1): Monoaminergic, Orexinergic, GABA-Ergic, and Anti-Inflammatory Agents. Frontiers in Pharmacology, 0, 13, .	1.6	15
733	Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies. Journal of Psychiatry and Neuroscience, 2022, 47, E218-E221.	1.4	3

#	ARTICLE	IF	CITATIONS
734	Validation of the forced swim test in <i>Drosophila</i> , and its use to demonstrate psilocybin has long-lasting antidepressant-like effects in flies. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
735	Sustained effects of single doses of classical psychedelics in humans. <i>Neuropsychopharmacology</i> , 2023, 48, 145-150.	2.8	21
736	Magic Mushrooms and Their Medicinal Use. <i>Ellipsis A Journal of Art Ideas and Literature</i> , 0, 47, .	0.0	0
737	Psychedelic therapy for body dysmorphic disorder. <i>Journal of Psychedelic Studies</i> , 2022, 6, 23-30.	0.5	1
738	Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions. <i>Journal of Psychedelic Studies</i> , 2022, 6, 10-22.	0.5	1
739	Psychedelic-Assisted Psychotherapy – A Systematic Review of Associated Psychological Interventions. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	17
740	Unravelling a New Conformer of Psilocin Through Computational Methods. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
741	Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
742	Mysticizing medicine: incorporating nondualism into the training of psychedelic guides. <i>Interdisciplinary Science Reviews</i> , 2023, 48, 752-767.	1.0	1
743	Psychedelics in the treatment of unipolar and bipolar depression. <i>International Journal of Bipolar Disorders</i> , 2022, 10, .	0.8	8
744	Potential benefits and harms: a review of poisonous mushrooms in the world. <i>Fungal Biology Reviews</i> , 2022, 42, 56-68.	1.9	8
745	Rapid-Response Treatments for Depression and Requests for Physician-Assisted Death: An Ethical Analysis. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 1255-1262.	0.6	1
746	Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy. <i>CNS Spectrums</i> , 2023, 28, 416-426.	0.7	6
747	Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	5
748	Singing in tune: Carl Jung and The Red Book. <i>Sleep Health</i> , 2022, , .	1.3	0
749	Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	70
750	Psychedelic drugs for psychiatric disorders. <i>Journal of the Neurological Sciences</i> , 2022, 440, 120332.	0.3	3
751	Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care. <i>Neuropharmacology</i> , 2022, 216, 109174.	2.0	18

#	ARTICLE	IF	CITATIONS
752	Reduced death anxiety and obsessive beliefs as mediators of the therapeutic effects of psychedelics on obsessive compulsive disorder symptomology. <i>Clinical Psychologist</i> , 0, , 1-16.	0.5	4
753	Buddhist-like opposite diminishing and non-judging during ketamine infusion are associated with antidepressant response: an open-label personalized-dosing study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
754	Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 140, 104793.	2.9	54
755	5-HT _{2A} SNPs Alter the Pharmacological Signaling of Potentially Therapeutic Psychedelics. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2386-2398.	1.7	13
756	The illusion of knowledge in the emerging field of psychedelic research. <i>New Ideas in Psychology</i> , 2022, 67, 100967.	1.2	5
757	Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling. <i>Neuropharmacology</i> , 2022, 218, 109220.	2.0	16
758	Examining Attitudes to Psilocybin: Should Candidates for Medical Psilocybin be Required to Pass a Contextual Suitability Test?. <i>Journal of Humanistic Psychology</i> , 0, , 002216782211103.	1.4	0
759	Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. <i>Journal of Psychopharmacology</i> , 2022, 36, 1100-1117.	2.0	54
760	Effective Connectivity of Functionally Anticorrelated Networks Under Lysergic Acid Diethylamide. <i>Biological Psychiatry</i> , 2023, 93, 224-232.	0.7	10
761	Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review. <i>Current Psychiatry Reports</i> , 2022, 24, 573-581.	2.1	9
762	Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample. <i>Journal of Psychopharmacology</i> , 2022, 36, 932-942.	2.0	34
763	The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world. <i>Psychopharmacology</i> , 2022, 239, 3461-3483.	1.5	32
764	Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines. <i>Neuropharmacology</i> , 2022, 219, 109214.	2.0	11
765	The Association of Classic Serotonergic Psychedelic Use and Intention of Future Use with Nature Relatedness. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 402-410.	1.0	4
766	The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2023, 68, 5-21.	0.9	21
767	Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder. <i>JAMA Psychiatry</i> , 2022, 79, 953.	6.0	217
768	Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying. <i>PLoS ONE</i> , 2022, 17, e0271926.	1.1	11
769	Psilocybin and the Meaning Response: Exploring the Healing Process in a Retreat Setting in Jamaica. <i>Anthropology of Consciousness</i> , 0, , .	0.5	1

#	ARTICLE	IF	CITATIONS
770	Adolescent and adult time trends in US hallucinogen use, 2002–19: any use, and use of ecstasy, LSD and PCP. <i>Addiction</i> , 2022, 117, 3099-3109.	1.7	31
771	Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States. <i>International Journal of Drug Policy</i> , 2022, 108, 103816.	1.6	4
772	Towards an understanding of psychedelic-induced neuroplasticity. <i>Neuropsychopharmacology</i> , 2023, 48, 104-112.	2.8	65
773	Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002–2019. <i>Addictive Behaviors Reports</i> , 2022, 16, 100454.	1.0	7
774	Raising awareness: The implementation of medical cannabis and psychedelics used as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer. <i>Drug Science, Policy and Law</i> , 2022, 8, 205032452211143.	0.6	0
775	Creative Approaches to Treating the Dread of Death. , 2022, , 75-92.		1
776	Plantes psychotropes, médecines traditionnelles autochtones du Pérou et renaissance psychédélique. <i>Drogues, Santé Et Société</i> , 0, 20, 90-116.	0.1	0
777	Macro dosing to micro dosing with psychedelics: Clinical, social, and cultural perspectives. <i>Transcultural Psychiatry</i> , 2022, 59, 665-674.	0.9	4
780	A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review. <i>CNS Drugs</i> , 2022, 36, 1031-1047.	2.7	5
781	The Emerging Field of Psychedelic Psychotherapy. <i>Current Psychiatry Reports</i> , 2022, 24, 583-590.	2.1	4
782	The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns. <i>American Journal of Geriatric Psychiatry</i> , 2023, 31, 44-53.	0.6	10
783	The use of classic psychedelics among adults: a Danish online survey study. <i>Nordic Journal of Psychiatry</i> , 2023, 77, 367-378.	0.7	5
784	Esketamine and Psilocybin—The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11450.	1.8	6
785	The psychedelic escape from depression. <i>Nature</i> , 2022, 609, S87-S89.	13.7	5
786	Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience. <i>Journal of Psychedelic Studies</i> , 2022, 6, 111-136.	0.5	4
787	The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry. <i>Cureus</i> , 2022, , .	0.2	7
788	Predictors of attitudes toward psychedelics among psychologists in the USA. <i>Drugs: Education, Prevention and Policy</i> , 2023, 30, 543-549.	0.8	0
789	Psychosocial and Integrative Oncology: Interventions Across the Disease Trajectory. <i>Annual Review of Psychology</i> , 2023, 74, 457-487.	9.9	5

#	ARTICLE	IF	CITATIONS
790	Psychedelics and mindfulness: A systematic review and meta-analysis. <i>Journal of Psychedelic Studies</i> , 2022, 6, 137-153.	0.5	3
791	Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 501-517.	1.0	7
792	Microdosing psilocybin for chronic pain: a case series. <i>Pain</i> , 2023, 164, 698-702.	2.0	8
793	Discovery of \hat{I}^2 -Arrestin-Biased 25CN-NBOH-Derived 5-HT _{2A} Receptor Agonists. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 12031-12043.	2.9	11
794	Facing death, returning to life: A qualitative analysis of MDMA-assisted therapy for anxiety associated with life-threatening illness. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	4
795	Self-Transcendent Positive Emotions as a Potential Mechanism Underpinning the Effects of Meaningful Psychedelic Experiences on Connectedness to Nature. <i>Ecopsychology</i> , 0, , .	0.8	1
796	Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N-dimethyltryptamine – Implications for dose considerations. <i>Clinical and Translational Science</i> , 2022, 15, 2928-2937.	1.5	11
797	Christianity and Psychedelic Medicine: A Pastoral Approach. <i>Christian Bioethics</i> , 2023, 29, 31-57.	0.1	1
798	Neural Mechanisms and Psychology of Psychedelic Ego Dissolution. <i>Pharmacological Reviews</i> , 2022, 74, 876-917.	7.1	20
799	Lysergic Acid Diethylamide – Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. <i>Biological Psychiatry</i> , 2023, 93, 215-223.	0.7	79
800	Psychedelic-Assisted Therapies in Patients With Serious Illness: Opportunities and Challenges. <i>Psychiatric Annals</i> , 2022, 52, 359-364.	0.1	1
801	Seeing in Visionary and Mystical Experience: A Perceptual and Cognitive-Semantic Account. <i>Cognitive Semantics</i> , 2022, 8, 323-344.	0.4	0
802	Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis. <i>Pharmacological Reviews</i> , 2022, 74, 984-1029.	7.1	10
803	Animal Behavior in Psychedelic Research. <i>Pharmacological Reviews</i> , 2022, 74, 1176-1205.	7.1	5
804	Ketamine-assisted meaning-centered psychotherapy for a patient with severe suicidal behavior. <i>Palliative and Supportive Care</i> , 2023, 21, 362-364.	0.6	1
805	Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2023, 322, 194-204.	2.0	20
806	Conformational Landscape and Properties of Psilocybin: A Computational Approach. <i>ChemistrySelect</i> , 2022, 7, .	0.7	2
807	Preparing for the Bursting of the Psychedelic Hype Bubble. <i>JAMA Psychiatry</i> , 2022, 79, 943.	6.0	38

#	ARTICLE	IF	CITATIONS
808	A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 581-588.	0.7	7
809	Hallucinogenic Drugs. , 2022, , 267-298.		0
810	Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	11
811	A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs. <i>European Neuropsychopharmacology</i> , 2022, 64, 44-60.	0.3	13
812	Therapeutic Choice in the SUDs Treatment. , 2022, , 321-343.		0
813	Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM) Tj ETQq1 1 0.784314 rgBT /Over	1.0	14
814	Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.0	7
815	The Efficacy of Psychedelic-Assisted Therapy in Managing Post-traumatic Stress Disorder (PTSD): A New Frontier?. <i>Cureus</i> , 2022, , .	0.2	2
816	Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapyâ€”A systematized review. <i>Journal of Psychopharmacology</i> , 2022, 36, 1191-1207.	2.0	7
817	Study protocol for â€œMDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle studyâ€• <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	1
818	Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 434-444.	1.0	1
819	Origins of Dualism and Nondualism in the History of Religion and Spiritual Practice. <i>Religions</i> , 2022, 13, 1004.	0.3	0
820	Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality. <i>Scientific Reports</i> , 2022, 12, .	1.6	16
821	The neural basis of psychedelic action. <i>Nature Neuroscience</i> , 2022, 25, 1407-1419.	7.1	85
822	Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. <i>New England Journal of Medicine</i> , 2022, 387, 1637-1648.	13.9	304
823	Belief changes associated with psychedelic use. <i>Journal of Psychopharmacology</i> , 2023, 37, 80-92.	2.0	10
826	The perceptions of cancer health-care practitioners in New Zealand and the USA toward psychedelic-assisted therapy with cancer patients: A cross-sectional survey. <i>Palliative and Supportive Care</i> , 0, , 1-10.	0.6	1
827	Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2022, 123, 106976.	0.8	3

#	ARTICLE	IF	CITATIONS
828	Role of interaction of mGlu2 and 5-HT2A receptors in antipsychotic effects. <i>Pharmacology Biochemistry and Behavior</i> , 2022, 221, 173474.	1.3	5
829	The Missing Piece? A Case for Microglia's Prominent Role in the Therapeutic Action of Anesthetics, Ketamine, and Psychedelics. <i>Neurochemical Research</i> , 2023, 48, 1129-1166.	1.6	8
830	Mushrooms, psilocybin. , 2024, , 567-569.		0
831	Hallucinogens as Therapeutic Agents: Past, Present, and Future. , 2022, , 975-986.		0
832	Psychedelic Psychodynamics: Relational Knowing and the Unthought Known. <i>Psychoanalytic Dialogues</i> , 2022, 32, 484-496.	0.2	3
833	Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants. <i>International Journal of Neuropsychopharmacology</i> , 2023, 26, 97-106.	1.0	27
834	Body mass index (BMI) does not predict responses to psilocybin. <i>Journal of Psychopharmacology</i> , 2023, 37, 107-116.	2.0	2
835	Psychedelic-Assisted Therapy for People with Eating Disorders. <i>Current Psychiatry Reports</i> , 2022, 24, 767-775.	2.1	5
837	Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	6
838	Psychedelics and Neural Plasticity: Therapeutic Implications. <i>Journal of Neuroscience</i> , 2022, 42, 8439-8449.	1.7	19
840	Psychedelic VR Experience: An Exploratory Study on Cosmic Flow. , 2022, , .		1
841	More than meets the eye: The role of sensory dimensions in psychedelic brain dynamics, experience, and therapeutics. <i>Neuropharmacology</i> , 2023, 223, 109300.	2.0	15
842	Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments. <i>Brain, Behavior, & Immunity - Health</i> , 2022, 26, 100554.	1.3	8
843	Ethical Issues Regarding Nonsubjective Psychedelics as Standard of Care. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2022, 31, 464-471.	0.5	10
844	Psychedelics as Standard of Care? Many Questions Remain. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2022, 31, 477-481.	0.5	2
845	Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation. <i>Comprehensive Psychoneuroendocrinology</i> , 2023, 13, 100163.	0.7	2
846	Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients. <i>Journal of Affective Disorders</i> , 2023, 323, 592-597.	2.0	27
847	Considerations in assessing the abuse potential of psychedelics during drug development. <i>Neuropharmacology</i> , 2023, 224, 109352.	2.0	3

#	ARTICLE	IF	CITATIONS
848	Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines. <i>Neuropharmacology</i> , 2023, 225, 109375.	2.0	6
849	The Varieties of Psychedelic Law. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
850	“Drugs of Abuse” as a “New Antidepressant” - A Review on Pharmacological Mechanisms, Antidepressant Effects, and Abuse Potential. <i>Journal of Korean Neuropsychiatric Association</i> , 2022, 61, 243.	0.2	0
851	ĐĐ•ĐĐ•Đ;ĐĐĐ; ĐŸĐ;Đ•ĐŸĐžĐ”Đ•Đ•Đ†Đ\$ĐĐžĐ† Đ•Đ•ĐĐĐŸĐ†Đ† Đ•Đ•Đ†Đ† Đ—ĐĐ\$Đ•ĐĐĐ” Đ”Đ•Đ- Đ†Đ\$ĐĐĐ†ĐĐ”. <i>Likarska Sprava</i>		
852	The Altered States Database: Psychometric data from a systematic literature review. <i>Scientific Data</i> , 2022, 9, .	2.4	7
853	Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	5
854	Natural Hallucinogens in Mental Health. , 2022, 1, 87-88.		0
855	Psilocybin mushrooms for psychological and existential distress. <i>Canadian Family Physician</i> , 2022, 68, 823-827.	0.1	2
856	Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis. <i>Cureus</i> , 2022, , .	0.2	3
857	Effect of lysergic acid diethylamide (LSD) on reinforcement learning in humans. <i>Psychological Medicine</i> , 2023, 53, 6434-6445.	2.7	17
858	Exploratory investigation of a patient’s informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial. <i>Headache</i> , 2022, 62, 1383-1394.	1.8	13
859	Psychedelic/entactogen-assisted therapy for treatment of anxiety, depression and existential distress in adult palliative care. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	1
860	Therapeutic use of psilocybin: Practical considerations for dosing and administration. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	13
861	Psychedelics and fNIRS neuroimaging: exploring new opportunities. <i>Neurophotonics</i> , 2022, 10, .	1.7	5
862	Moderators of ayahuasca’s biological antidepressant action. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	4
863	In Becoming. Instability of Psychedelic Substances. <i>Etnografia Polska</i> , 2022, 66, 29-46.	0.0	0
864	A unified model of ketamine’s dissociative and psychedelic properties. <i>Journal of Psychopharmacology</i> , 2023, 37, 14-32.	2.0	8
865	Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. <i>Heliyon</i> , 2022, 8, e12135.	1.4	3

#	ARTICLE	IF	CITATIONS
866	“A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use. <i>PLoS ONE</i> , 2022, 17, e0279073.	1.1	4
867	The economics of psychedelic-assisted therapies: A research agenda. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	4
868	Journeying to Ixtlan: Ethics of Psychedelic Medicine and Research for Alzheimer’s Disease and Related Dementias. <i>AJOB Neuroscience</i> , 2023, 14, 107-123.	0.6	29
869	Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms. <i>Journal of Affective Disorders</i> , 2023, 324, 239-249.	2.0	7
870	Existential humility: strong tests of intellectual humility. <i>Journal of Positive Psychology</i> , 2023, 18, 259-263.	2.6	2
871	Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder. <i>Journal of Psychopharmacology</i> , 2023, 37, 3-13.	2.0	3
872	Psychedelic innovations and the crisis of psychopharmacology. <i>BioSocieties</i> , 0, , .	0.8	5
873	Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
874	The varieties of psychedelic law. <i>Neuropharmacology</i> , 2023, 226, 109399.	2.0	9
875	Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users” A National Survey Study. <i>Children</i> , 2022, 9, 1906.	0.6	0
876	Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of “magic mushroom” consumption. <i>Journal of Psychopharmacology</i> , 2023, 37, 49-60.	2.0	24
877	Lower-dose psycholytic therapy “ A neglected approach. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	13
878	Do Psychedelic Trips Open the Door to Messages from God, Spirits, Transcendent Realities, or the Devil? Links with Attitudes About Psychedelics, Opinions About Legalization, and Interest in Personal Use. <i>International Journal for the Psychology of Religion</i> , The, 0, , 1-19.	1.3	2
879	Research into Psychedelic-Assisted Psychotherapy for Anorexia Nervosa Should be Funded. <i>Journal of Bioethical Inquiry</i> , 0, , .	0.9	1
880	Consultation-Liaison Case Conference: Suicidal Ideation in a Patient at the End-of-Life. <i>Journal of the Academy of Consultation-Liaison Psychiatry</i> , 2023, 64, 371-382.	0.2	0
881	Use of the head-twitch response to investigate the structure-activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines. <i>Psychopharmacology</i> , 2023, 240, 115-126.	1.5	0
882	Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 822-831.	2.3	33
883	Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology. <i>Neurosurgery</i> , 2023, 92, 680-694.	0.6	2

#	ARTICLE	IF	CITATIONS
884	A neurophenomenological approach to non-ordinary states of consciousness: hypnosis, meditation, and psychedelics. <i>Trends in Cognitive Sciences</i> , 2023, 27, 139-159.	4.0	18
885	Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms. <i>Psychopharmacology</i> , 2023, 240, 27-40.	1.5	5
886	Novel Perspective of Medicinal Mushroom Cultivations: A Review Case for "Magic" Mushrooms. <i>Agronomy</i> , 2022, 12, 3185.	1.3	7
887	Entheogenic Spirituality: Characteristics of Spiritually Motivated Psychedelics Use. <i>International Journal for the Psychology of Religion</i> , 2020, 1-17.	1.3	1
888	Toward Mapping Neurobehavioral Heterogeneity of Psychedelic Neurobiology in Humans. <i>Biological Psychiatry</i> , 2023, 93, 1061-1070.	0.7	23
889	An Integrative Review of Measures of Spirituality in Experimental Studies of Psilocybin in Serious Illness Populations. <i>American Journal of Hospice and Palliative Medicine</i> , 2023, 38, 104990912211477.	0.8	0
890	Thanatotherapy: How psychedelic-assisted psychotherapy and the near-death experience can mutually benefit one another. <i>Journal of Palliative Care</i> , 2022, 1, 99-109.		0
891	Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands. <i>Journal of Psychedelic Studies</i> , 2023, 6, 211-221.	0.5	22
892	Psilocin suppresses methamphetamine-induced hyperlocomotion and acquisition of conditioned place preference via D2R-mediated ERK signaling. <i>CNS Neuroscience and Therapeutics</i> , 2023, 29, 1-12.	1.9	3
893	Opening Death's Door: Psilocybin and Existential Suffering in Palliative Care. <i>Philosophy and Medicine</i> , 2023, 34, 235-262.	0.3	0
894	Psychedelics for Patients With Cancer: A Comprehensive Literature Review. <i>Annals of Pharmacotherapy</i> , 2023, 57, 1062-1075.	0.9	2
895	Utility of preclinical models in the study of psilocybin – a comprehensive review. <i>Neuroscience and Biobehavioral Reviews</i> , 2023, 143, 105046.	2.9	0
896	Shared and Distinct Brain Regions Targeted for Immediate Early Gene Expression by Ketamine and Psilocybin. <i>ACS Chemical Neuroscience</i> , 2023, 14, 468-480.	1.7	33
898	Post-traumatic stress symptoms, post-traumatic stress disorder, and post-traumatic growth among cancer survivors: a systematic scoping review of interventions. <i>Health Psychology Review</i> , 2024, 18, 41-74.	4.4	3
899	Conformational Landscape and Hydrogen Bonding Pattern of Psilocin: Computational Insights. <i>ChemistrySelect</i> , 2023, 8, 1-12.	0.7	2
900	Are psychedelics the answer to chronic pain: A review of current literature. <i>Pain Practice</i> , 2023, 23, 447-458.	0.9	6
901	Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. <i>Neuropharmacology</i> , 2023, 226, 109422.	2.0	16
902	Psilocybin for Depression: From Credibility to Feasibility, What's Missing?. <i>Pharmaceuticals</i> , 2023, 16, 68.	1.7	5

#	ARTICLE	IF	CITATIONS
903	Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial. <i>Journal of Psychedelic Studies</i> , 2023, 7, 1-11.	0.5	0
904	The costs and benefits of psychedelics on cognition and mood. <i>Neuron</i> , 2023, 111, 614-630.	3.8	7
905	Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT) _{2A} Receptor (5-HT _{2A} R), 5-HT _{2C} R, 5-HT _{1A} R, and Serotonin Transporter. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2023, 385, 62-75.	1.3	9
906	Educational Materials and Image Induction Increase Treatment Credibility. <i>Journal of Psychoactive Drugs</i> , 2024, 56, 56-65.	1.0	0
907	On the Edges: The Ethics of Human Studies with Psychedelic Substances. , 2023, , 153-171.		0
908	A scoping review of spirituality in relation to substance use disorders: Psychological, biological, and cultural issues. <i>Journal of Addictive Diseases</i> , 0, , 1-9.	0.8	2
909	A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. <i>Cell Reports</i> , 2023, 42, 112203.	2.9	28
910	A Single Administration of Psilocybin Persistently Rescues Cognitive Deficits Caused by Adolescent Chronic Restraint Stress Without Long-Term Changes in Synaptic Protein Gene Expression in a Rat Experimental System with Translational Relevance to Depression. , 2023, 1, 54-67.		5
911	Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective. <i>Frontiers in Psychology</i> , 0, 14, .	1.1	3
912	Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	4
913	Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders. <i>Neuropharmacology</i> , 2023, 231, 109504.	2.0	7
915	Reconsidering "dissociation" as a predictor of antidepressant efficacy for esketamine. <i>Psychopharmacology</i> , 2023, 240, 827-836.	1.5	8
916	LSD-induced increase of Ising temperature and algorithmic complexity of brain dynamics. <i>PLoS Computational Biology</i> , 2023, 19, e1010811.	1.5	4
917	Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. <i>Journal of Affective Disorders</i> , 2023, 327, 120-127.	2.0	32
918	Indole Alkaloids from Psychoactive Mushrooms: Chemical and Pharmacological Potential as Psychotherapeutic Agents. <i>Biomedicines</i> , 2023, 11, 461.	1.4	7
919	Recent Progress in Mind-Body Therapies in Cancer Care. <i>Current Oncology Reports</i> , 2023, 25, 293-307.	1.8	5
920	Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	8
921	N,N-dimethyltryptamine affects electroencephalography response in a concentration-dependent manner—A pharmacokinetic/pharmacodynamic analysis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 474-486.	1.3	5

#	ARTICLE	IF	CITATIONS
922	Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
923	Acute psilocybin enhances cognitive flexibility in rats. <i>Neuropsychopharmacology</i> , 2023, 48, 1011-1020.	2.8	11
924	Alkaloids from Fungi. , 2023, , 529-554.		0
925	A Question of Dose and Context: LSD, Peyote and Chemical Interactions, Human Variation, and Interpretation. , 2022, , 33-133.		0
927	Typology of Users of Psychedelics and Alike Psychoactive Substances in Czechia: Results of the National Online Survey. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 601-611.	1.0	0
928	Lysergic Acid Diethylamide Alters the Effects of Brain Stimulation in Rodents. , 2023, 1, 43-53.		0
929	Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors. <i>Journal of Psychopharmacology</i> , 2023, 37, 660-678.	2.0	6
930	Psychedelic replications in virtual reality and their potential as a therapeutic instrument: an open-label feasibility study. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	4
931	The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study. <i>International Medical Case Reports Journal</i> , 0, Volume 16, 109-115.	0.3	1
932	Restructuring insight: An integrative review of insight in problem-solving, meditation, psychotherapy, delusions and psychedelics. <i>Consciousness and Cognition</i> , 2023, 110, 103494.	0.8	7
933	The Impact of Psychedelic Drugs on Anxiety and Depression in Advanced Cancer or other Life-threatening Disease. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 0, Publish Ahead of Print, .	0.6	2
934	Validation of sociocultural attitudes towards appearance questionnaire and its associations with body-related outcomes and eating disorders among Chinese adolescents. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	0
935	Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress. , 0, , .		0
936	Psychedelics: preclinical insights provide directions for future research. <i>Neuropsychopharmacology</i> , 2024, 49, 119-127.	2.8	7
937	Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 612-630.	1.0	0
938	Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. <i>Journal of Psychopharmacology</i> , 2023, 37, 698-706.	2.0	43
939	Neural Network Modulation of Ayahuasca: A Systematic Review of Human Studies. , 2023, 2, 76-91.		0
941	Psychedelics and the Entropic Brain Beyond the Self. <i>International Journal for the Psychology of Religion</i> , The, 0, , 1-17.	1.3	0

#	ARTICLE	IF	CITATIONS
942	The need for establishing best practices and gold standards in psychedelic medicine. <i>Journal of Affective Disorders</i> , 2023, 332, 47-54.	2.0	7
943	Psychotherapy with Psilocybin for Depression: Systematic Review. <i>Behavioral Sciences (Basel)</i> , 2023, 12, 1071-1084.	1.0	4
944	Antidepressants for the treatment of depression in people with cancer. <i>The Cochrane Library</i> , 2023, .	1.5	2
945	Examining the Therapeutic Effect of Ceremonial Ayahuasca on Narcissistic Personality and Antagonistic Externalizing in Adults. <i>Journal of Personality Disorders</i> , 2023, 37, 131-155.	0.8	3
946	Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs. <i>Neuropharmacology</i> , 2023, 233, 109528.	2.0	7
947	Psychedelics, entropic brain theory, and the taxonomy of conscious states: a summary of debates and perspectives. <i>Neuroscience of Consciousness</i> , 2023, 2023, .	1.4	5
948	Psilocybin to promote synaptogenesis in the brains of patients with mild cognitive impairment. <i>Medical Hypotheses</i> , 2023, , 111068.	0.8	0
949	Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding. <i>Translational Psychiatry</i> , 2023, 13, .	2.4	5
950	Predictors of Medical Students' Perceptions of Psilocybin-Assisted Therapy for Use in Medical Practice. <i>Cureus</i> , 2023, , .	0.2	3
951	With great power comes great vulnerability: an ethical analysis of psychedelics' therapeutic mechanisms proposed by the REBUS hypothesis. <i>Journal of Medical Ethics</i> , 2023, 49, 826-832.	1.0	3
952	Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder. <i>JAMA Oncology</i> , 2023, 9, 864.	3.4	8
953	Psilocybin in Palliative Care: An Update. <i>Current Geriatrics Reports</i> , 2023, 12, 50-59.	1.1	1
954	G protein coupled receptors as targets for transformative neuropsychiatric therapeutics. <i>American Journal of Physiology - Cell Physiology</i> , 0, , .	2.1	1
955	Depression and anxiety in glioma patients. <i>Neuro-Oncology Practice</i> , 2023, 10, 335-343.	1.0	2
977	How medical cannabis may influence the future of Western medicine. , 2023, , 3-14.		0
1009	The Health and Clinical Benefits of Medicinal Fungi. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2023, , .	0.6	0
1012	Therapeutic mechanisms of psychedelics and entactogens. <i>Neuropsychopharmacology</i> , 2024, 49, 104-118.	2.8	4
1014	Modulating cyclic nucleotides pathways by bioactive compounds in combatting anxiety and depression disorders. <i>Molecular Biology Reports</i> , 0, , .	1.0	0

#	ARTICLE	IF	CITATIONS
1016	The Potential for Psychedelics to Improve Coping Skills and Resilience in Persons With Newly Diagnosed Mild Cognitive Impairment or Early Alzheimer's Disease. <i>Current Geriatrics Reports</i> , 2023, 12, 149-155.	1.1	1
1035	Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics. <i>Molecular Psychiatry</i> , 2023, 28, 3595-3612.	4.1	4
1036	The role of neurotrophic factors in novel, rapid psychiatric treatments. <i>Neuropsychopharmacology</i> , 2024, 49, 227-245.	2.8	6
1053	Preclinical models of treatment-resistant depression: challenges and perspectives. <i>Pharmacological Reports</i> , 2023, 75, 1326-1340.	1.5	0
1067	Drugs and Psychedelics in Tourism. <i>Advances in Hospitality, Tourism and the Services Industry</i> , 2023, , 197-223.	0.2	0
1070	Medical Use of Cannabinoids and Psychedelic Compounds. , 2023, , 1-30.		0
1081	Psychoactive drugs. , 2024, , 397-407.		0
1083	Utilizing Chatbots as Predictive Tools for Anxiety and Depression: A Bibliometric Review. <i>Communications in Computer and Information Science</i> , 2024, , 138-153.	0.4	0
1084	Cardiovascular safety of psychedelic medicine: current status and future directions. <i>Pharmacological Reports</i> , 0, , .	1.5	1
1086	Case report: Maintaining altered states of consciousness over repeated ketamine infusions may be key to facilitate long-lasting antidepressant effects: some initial lessons from a personalized-dosing single-case study. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	0
1091	The possible place for psychedelics in pharmacotherapy of mental disorders. <i>Pharmacological Reports</i> , 2023, 75, 1313-1325.	1.5	2
1092	Mindfulness meditation and psychedelics: potential synergies and commonalities. <i>Pharmacological Reports</i> , 2023, 75, 1398-1409.	1.5	1
1094	Psilocybin and Other Classic Psychedelics in Depression. <i>Current Topics in Behavioral Neurosciences</i> , 2023, , .	0.8	0
1097	THE SEROTONIN 5-HT _{2A} RECEPTOR AS AN EVOLVING NEUROTHERAPEUTIC TARGET. <i>Medicinal Chemistry Reviews</i> , 0, , 53-81.	0.1	0
1112	Introducing psychedelics to end-of-life mental healthcare. , 2023, 1, 920-922.		0
1136	Disorders due to Substance Use: Hallucinogens and MDMA-Related Substances. , 2023, , 1-34.		0
1144	Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential. <i>Molecular Psychiatry</i> , 0, , .	4.1	0
1148	Exploring Psilocybin as a Tool for Studying Parkinsonism-Related Psychosis: A Narrative Review Supplemented with a Computational Approach. <i>IFMBE Proceedings</i> , 2024, , 530-547.	0.2	0

#	ARTICLE	IF	CITATIONS
1175	A Systematic Review of Interventions for Demoralization in Patients with Chronic Diseases. International Journal of Behavioral Medicine, 0, , .	0.8	0
1184	Integrating Therapies: A Rational, Personalised Approach to Metastatic Disease. , 2023, , 95-112.		0
1196	Bringing It Home and Carrying It Forward. , 2024, , 252-262.		0
1198	Integration Sessions. , 2024, , 204-251.		0
1199	INTRODUCTION: A New Approach for the Whole Person. , 2024, , 1-9.		0
1200	An Overview of Psychedelic-Assisted Therapy. , 2024, , 10-30.		0
1203	Medicine Sessions. , 2024, , 167-203.		0
1205	Preparation Sessions. , 2024, , 132-166.		0
1206	Considerations Prior to Meeting With a Participant. , 2024, , 93-131.		0
1207	EMBARK Mechanisms of Change in the Treatment of Depression. , 2024, , 70-92.		0
1208	Introduction to the EMBARK Approach. , 2024, , 31-69.		0
1214	Medical Use of Cannabinoids and Psychedelic Compounds. , 2024, , 1-29.		0